Trial Outcomes & Findings for A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants (NCT NCT04857892)

Results Overview

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3640254.

Recruitment status

COMPLETED

Study phase

PHASE1

Target enrollment

41 participants

Primary outcome timeframe

Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Results posted on

2024-03-12

Participant Flow

This was a randomized, open-label, single dose, crossover clinical study to assess relative bioavailability and food-effect of the fixed dose combination (FDC) of GSK3640254 and Dolutegravir (DTG) in healthy participants.

A total of 41 participants (23 participants in Part 1 and 18 participants in Part 2) were enrolled in the study.

Participant milestones

Participant milestones
Measure	Part 1: Cohort 1: Sequence ABC Participants received Treatment A as a single oral dose of GSK3640254 25 milligrams (mg) (2 tablets), GSK3640254 100 mg (1 tablet)/dolutegravir (DTG) 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.	Part 1: Cohort 2: Sequence BCA Participants received Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 on treatment period 3. There was washout period of 7 days between each treatment period.	Part 1: Cohort 3: Sequence CAB Participants received Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet) and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions (reference) on Day 1 in treatment period 2, further followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.	Part 2: Cohort 1: Sequence DE Participants received Treatment D as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 1, followed by Treatment E as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.	Part 2: Cohort 2: Sequence ED Participants received Treatment E as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 1, followed by Treatment D as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.
Part 1: Period 1 (Day 1) STARTED	9	7	7	0	0
Part 1: Period 1 (Day 1) COMPLETED	8	7	7	0	0
Part 1: Period 1 (Day 1) NOT COMPLETED	1	0	0	0	0
Part 1: Washout Period 1 (Up to 7 Days) STARTED	8	7	7	0	0
Part 1: Washout Period 1 (Up to 7 Days) COMPLETED	8	7	7	0	0
Part 1: Washout Period 1 (Up to 7 Days) NOT COMPLETED	0	0	0	0	0
Part 1: Period 2 (Day 1) STARTED	8	7	7	0	0
Part 1: Period 2 (Day 1) COMPLETED	8	7	7	0	0
Part 1: Period 2 (Day 1) NOT COMPLETED	0	0	0	0	0
Part 1: Washout Period 2 (Up to 7 Days) STARTED	8	7	7	0	0
Part 1: Washout Period 2 (Up to 7 Days) COMPLETED	6	6	6	0	0
Part 1: Washout Period 2 (Up to 7 Days) NOT COMPLETED	2	1	1	0	0
Part 1: Period 3 (Day 1) STARTED	6	6	6	0	0
Part 1: Period 3 (Day 1) COMPLETED	6	6	6	0	0
Part 1: Period 3 (Day 1) NOT COMPLETED	0	0	0	0	0
Part 2: Period 1 (Day 1) STARTED	0	0	0	9	9
Part 2: Period 1 (Day 1) COMPLETED	0	0	0	9	9
Part 2: Period 1 (Day 1) NOT COMPLETED	0	0	0	0	0
Part 2: Washout Period 1 (Up to 7 Days) STARTED	0	0	0	9	9
Part 2: Washout Period 1 (Up to 7 Days) COMPLETED	0	0	0	9	8
Part 2: Washout Period 1 (Up to 7 Days) NOT COMPLETED	0	0	0	0	1
Part 2: Period 2 (Day 1) STARTED	0	0	0	9	8
Part 2: Period 2 (Day 1) COMPLETED	0	0	0	9	8
Part 2: Period 2 (Day 1) NOT COMPLETED	0	0	0	0	0

Reasons for withdrawal

Reasons for withdrawal
Measure	Part 1: Cohort 1: Sequence ABC Participants received Treatment A as a single oral dose of GSK3640254 25 milligrams (mg) (2 tablets), GSK3640254 100 mg (1 tablet)/dolutegravir (DTG) 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.	Part 1: Cohort 2: Sequence BCA Participants received Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 on treatment period 3. There was washout period of 7 days between each treatment period.	Part 1: Cohort 3: Sequence CAB Participants received Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet) and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions (reference) on Day 1 in treatment period 2, further followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.	Part 2: Cohort 2: Sequence ED Participants received Treatment E as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 1, followed by Treatment D as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.
Part 1: Period 1 (Day 1) Adverse Event	1	0	0	0
Part 1: Washout Period 2 (Up to 7 Days) Withdrawal by Subject	2	1	1	0
Part 2: Washout Period 1 (Up to 7 Days) Protocol Violation	0	0	0	1

Baseline Characteristics

A Relative Bioavailability and Food-Effect Study of the Fixed Dose Combination of GSK3640254 and Dolutegravir (DTG) in Healthy Participants

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure	Part 1: Cohort 1: Sequence ABC n=9 Participants Participants received Treatment A as a single oral dose of GSK3640254 25 milligrams (mg) (2 tablets), GSK3640254 100 mg (1 tablet)/dolutegravir (DTG) 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.	Part 1: Cohort 2: Sequence BCA n=7 Participants Participants received Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 2, further followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions on Day 1 on treatment period 3. There was washout period of 7 days between each treatment period.	Part 1: Cohort 3: Sequence CAB n=7 Participants Participants received Treatment C as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 bilayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 1 followed by Treatment A as a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet) and DTG 50 mg (1 tablet) administered together under moderate fat and calorie conditions (reference) on Day 1 in treatment period 2, further followed by Treatment B as a single oral dose of GSK3640254/DTG, 150 mg/50 mg (1 monolayer tablet) FDC administered under moderate fat and calorie conditions on Day 1 in treatment period 3. There was washout period of 7 days between each treatment period.	Part 2: Cohort 1: Sequence DE n=9 Participants Participants received Treatment D as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 1, followed by Treatment E as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.	Part 2: Cohort 2: Sequence ED n=9 Participants Participants received Treatment E as a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in treatment Period 1, followed by Treatment D as a single oral dose of selected FDC of GSK3640254/DTG, 150 mg/50 mg administered under high fat and calorie conditions on Day 1 in treatment Period 2. There was washout period of 7 days between each treatment period.	Total n=41 Participants Total of all reporting groups
Age, Customized <=18 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Age, Customized 19-64 years	9 Participants n=5 Participants	7 Participants n=7 Participants	7 Participants n=5 Participants	9 Participants n=4 Participants	9 Participants n=21 Participants	41 Participants n=10 Participants
Age, Customized >= 65 years	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	0 Participants n=10 Participants
Sex: Female, Male Female	3 Participants n=5 Participants	4 Participants n=7 Participants	4 Participants n=5 Participants	5 Participants n=4 Participants	2 Participants n=21 Participants	18 Participants n=10 Participants
Sex: Female, Male Male	6 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	4 Participants n=4 Participants	7 Participants n=21 Participants	23 Participants n=10 Participants
Race/Ethnicity, Customized Black or African American	3 Participants n=5 Participants	3 Participants n=7 Participants	3 Participants n=5 Participants	6 Participants n=4 Participants	3 Participants n=21 Participants	18 Participants n=10 Participants
Race/Ethnicity, Customized White-White/Caucasian/European Heritage	6 Participants n=5 Participants	3 Participants n=7 Participants	4 Participants n=5 Participants	3 Participants n=4 Participants	4 Participants n=21 Participants	20 Participants n=10 Participants
Race/Ethnicity, Customized Multiple	0 Participants n=5 Participants	1 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	0 Participants n=21 Participants	1 Participants n=10 Participants
Race/Ethnicity, Customized American Indian or Alaska Native	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants
Race/Ethnicity, Customized Asian- South East Asian Heritage	0 Participants n=5 Participants	0 Participants n=7 Participants	0 Participants n=5 Participants	0 Participants n=4 Participants	1 Participants n=21 Participants	1 Participants n=10 Participants

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population consisted of all participants who underwent plasma PK sampling and had evaluable PK parameters estimated. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for pharmacokinetic (PK) analysis of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=18 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=16 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Area Under the Plasma Concentration-time Curve From Time 0 Extrapolated to Infinity (AUC[0-inf]) of GSK3640254	22.13 Hours*microgram per milliliter Geometric Coefficient of Variation 46.8	21.93 Hours*microgram per milliliter Geometric Coefficient of Variation 36.6	22.63 Hours*microgram per milliliter Geometric Coefficient of Variation 38.0

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Area Under the Plasma Concentration-time Curve From Time 0 to Time t (AUC[0-t]) of GSK3640254	17.62 Hours*microgram per milliliter Geometric Coefficient of Variation 55.4	19.14 Hours*microgram per milliliter Geometric Coefficient of Variation 42.9	18.69 Hours*microgram per milliliter Geometric Coefficient of Variation 42.4

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Maximum Observed Concentration (Cmax) of GSK3640254	0.7382 Microgram per milliliter Geometric Coefficient of Variation 40.3	0.7610 Microgram per milliliter Geometric Coefficient of Variation 33.5	0.7579 Microgram per milliliter Geometric Coefficient of Variation 40.1

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of DTG.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: AUC(0-inf) of DTG	74.18 Hours*microgram per milliliter Geometric Coefficient of Variation 30.7	82.13 Hours*microgram per milliliter Geometric Coefficient of Variation 26.1	80.53 Hours*microgram per milliliter Geometric Coefficient of Variation 34.7

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of DTG.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: AUC(0-t) of DTG	68.91 Hours*microgram per milliliter Geometric Coefficient of Variation 32.5	77.89 Hours*microgram per milliliter Geometric Coefficient of Variation 29.0	73.44 Hours*microgram per milliliter Geometric Coefficient of Variation 37.0

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of DTG.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Cmax of DTG	4.182 Microgram per milliliter Geometric Coefficient of Variation 18.5	4.432 Microgram per milliliter Geometric Coefficient of Variation 17.8	4.264 Microgram per milliliter Geometric Coefficient of Variation 23.2

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=13 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: AUC(0-inf) of GSK3640254	21.39 Hours*microgram per milliliter Geometric Coefficient of Variation 38.0	6.622 Hours*microgram per milliliter Geometric Coefficient of Variation 77.4	—

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period.

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=13 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: AUC(0-t) of GSK3640254	19.33 Hours*microgram per milliliter Geometric Coefficient of Variation 36.6	6.027 Hours*microgram per milliliter Geometric Coefficient of Variation 78.8	—

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected at indicated time points for PK analysis of GSK3640254.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=13 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Cmax of GSK3640254	0.6093 Microgram per milliliter Geometric Coefficient of Variation 41.3	0.2193 Microgram per milliliter Geometric Coefficient of Variation 92.1	—

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of DTG.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: AUC(0-inf) of DTG	85.07 Hours*microgram per milliliter Geometric Coefficient of Variation 29.0	64.61 Hours*microgram per milliliter Geometric Coefficient of Variation 31.5	—

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of DTG.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: AUC(0-t) of DTG	83.18 Hours*microgram per milliliter Geometric Coefficient of Variation 28.2	63.17 Hours*microgram per milliliter Geometric Coefficient of Variation 31.0	—

PRIMARY outcome

Timeframe: Pre-dose, 30 minutes, 1 hour, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 6, 8, 12, 24, 48, 72, 96 hours post dose in each treatment period

Population: PK Parameter Population

Blood samples were collected at indicated time points for PK analysis of DTG.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Cmax of DTG	4.000 Microgram per milliliter Geometric Coefficient of Variation 21.1	3.273 Microgram per milliliter Geometric Coefficient of Variation 28.4	—

SECONDARY outcome

Timeframe: Up to 17 days

Population: Safety Population consisted of all participants who received at least one dose of study intervention.

An adverse event (AE) is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Non-Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) Non-SAEs	0 Participants	0 Participants	1 Participants
Part 1: Number of Participants With Non-Serious Adverse Events (Non-SAEs) and Serious Adverse Events (SAEs) SAEs	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to 9 days

Population: Safety Population

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study treatment, whether or not considered related to the study treatment. A SAE is defined as any serious adverse event that, at any dose: results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect or other situations as per medical or scientific judgment. Adverse events which were not Serious Adverse Events were considered as Non-Serious adverse events.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Non-SAEs and SAEs Non-SAEs	1 Participants	2 Participants	—
Part 2: Number of Participants With Non-SAEs and SAEs SAEs	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, leukocytes and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Hematology Parameter: Hemoglobin Baseline (Day -1)	139.8 Grams per liter Standard Deviation 16.04	142.7 Grams per liter Standard Deviation 16.64	138.8 Grams per liter Standard Deviation 16.55
Part 1: Absolute Values for Hematology Parameter: Hemoglobin Day 2	141.1 Grams per liter Standard Deviation 15.57	143.1 Grams per liter Standard Deviation 15.14	139.2 Grams per liter Standard Deviation 16.11
Part 1: Absolute Values for Hematology Parameter: Hemoglobin Day 5	134.8 Grams per liter Standard Deviation 14.74	135.0 Grams per liter Standard Deviation 15.19	141.8 Grams per liter Standard Deviation 14.89
Part 1: Absolute Values for Hematology Parameter: Hemoglobin Day 7	145.8 Grams per liter Standard Deviation 14.97	140.6 Grams per liter Standard Deviation 18.11	138.1 Grams per liter Standard Deviation 16.11

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values for Hematology Parameter: Hemoglobin Baseline (Day -1)	139.8 Grams per liter Standard Deviation 15.66	138.4 Grams per liter Standard Deviation 14.09	—
Part 2: Absolute Values for Hematology Parameter: Hemoglobin Day 2	141.0 Grams per liter Standard Deviation 15.86	140.7 Grams per liter Standard Deviation 16.62	—
Part 2: Absolute Values for Hematology Parameter: Hemoglobin Day 5	143.1 Grams per liter Standard Deviation 11.22	135.6 Grams per liter Standard Deviation 18.04	—
Part 2: Absolute Values for Hematology Parameter: Hemoglobin Day 7	134.3 Grams per liter Standard Deviation 15.82	144.2 Grams per liter Standard Deviation 11.11	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Baseline (Day -1)	86.45 Femtoliter Standard Deviation 4.446	86.33 Femtoliter Standard Deviation 4.376	86.94 Femtoliter Standard Deviation 4.244
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 2	86.26 Femtoliter Standard Deviation 4.324	86.51 Femtoliter Standard Deviation 4.392	86.99 Femtoliter Standard Deviation 4.171
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 5	86.48 Femtoliter Standard Deviation 4.642	86.08 Femtoliter Standard Deviation 4.923	87.58 Femtoliter Standard Deviation 4.668
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 7	86.12 Femtoliter Standard Deviation 4.256	87.28 Femtoliter Standard Deviation 4.120	86.09 Femtoliter Standard Deviation 4.703

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Baseline (Day -1)	84.55 Femtoliter Standard Deviation 5.141	84.89 Femtoliter Standard Deviation 4.925	—
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 2	84.30 Femtoliter Standard Deviation 4.926	84.74 Femtoliter Standard Deviation 5.146	—
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 5	84.33 Femtoliter Standard Deviation 3.593	84.50 Femtoliter Standard Deviation 6.116	—
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 7	84.37 Femtoliter Standard Deviation 5.841	85.29 Femtoliter Standard Deviation 4.042	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Baseline (Day -1)	4.757 10^12 cells per liter Standard Deviation 0.4773	4.850 10^12 cells per liter Standard Deviation 0.5190	4.686 10^12 cells per liter Standard Deviation 0.4967
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Day 2	4.822 10^12 cells per liter Standard Deviation 0.4863	4.855 10^12 cells per liter Standard Deviation 0.4740	4.700 10^12 cells per liter Standard Deviation 0.4353
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Day 5	4.658 10^12 cells per liter Standard Deviation 0.4331	4.558 10^12 cells per liter Standard Deviation 0.3547	4.710 10^12 cells per liter Standard Deviation 0.5284
Part 1: Absolute Values for Hematology Parameter: Erythrocytes Day 7	4.939 10^12 cells per liter Standard Deviation 0.5032	4.752 10^12 cells per liter Standard Deviation 0.5521	4.700 10^12 cells per liter Standard Deviation 0.4412

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Baseline (Day -1)	4.914 10^12 cells per liter Standard Deviation 0.5070	4.853 10^12 cells per liter Standard Deviation 0.5060	—
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Day 2	4.958 10^12 cells per liter Standard Deviation 0.4930	4.913 10^12 cells per liter Standard Deviation 0.5727	—
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Day 5	4.976 10^12 cells per liter Standard Deviation 0.4861	4.787 10^12 cells per liter Standard Deviation 0.4171	—
Part 2: Absolute Values for Hematology Parameter: Erythrocytes Day 7	4.760 10^12 cells per liter Standard Deviation 0.5021	4.942 10^12 cells per liter Standard Deviation 0.5117	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Hematology Parameters: Hematocrit Baseline (Day -1)	0.4110 Proportion of red blood cells in blood Standard Deviation 0.04343	0.4181 Proportion of red blood cells in blood Standard Deviation 0.04561	0.4070 Proportion of red blood cells in blood Standard Deviation 0.04490
Part 1: Absolute Values for Hematology Parameters: Hematocrit Day 2	0.4156 Proportion of red blood cells in blood Standard Deviation 0.04297	0.4195 Proportion of red blood cells in blood Standard Deviation 0.04087	0.4087 Proportion of red blood cells in blood Standard Deviation 0.04260
Part 1: Absolute Values for Hematology Parameters: Hematocrit Day 5	0.4025 Proportion of red blood cells in blood Standard Deviation 0.03930	0.3922 Proportion of red blood cells in blood Standard Deviation 0.03854	0.4117 Proportion of red blood cells in blood Standard Deviation 0.04206
Part 1: Absolute Values for Hematology Parameters: Hematocrit Day 7	0.4246 Proportion of red blood cells in blood Standard Deviation 0.04202	0.4144 Proportion of red blood cells in blood Standard Deviation 0.04936	0.4047 Proportion of red blood cells in blood Standard Deviation 0.04553

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: hematocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values for Hematology Parameters: Hematocrit Baseline (Day -1)	0.4145 Proportion of red blood cells in blood Standard Deviation 0.04184	0.4106 Proportion of red blood cells in blood Standard Deviation 0.03687	—
Part 2: Absolute Values for Hematology Parameters: Hematocrit Day 2	0.4173 Proportion of red blood cells in blood Standard Deviation 0.04269	0.4153 Proportion of red blood cells in blood Standard Deviation 0.04510	—
Part 2: Absolute Values for Hematology Parameters: Hematocrit Day 5	0.4183 Proportion of red blood cells in blood Standard Deviation 0.03167	0.4044 Proportion of red blood cells in blood Standard Deviation 0.04641	—
Part 2: Absolute Values for Hematology Parameters: Hematocrit Day 7	0.4004 Proportion of red blood cells in blood Standard Deviation 0.04078	0.4201 Proportion of red blood cells in blood Standard Deviation 0.03113	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Baseline (Day -1)	29.37 Picograms Standard Deviation 1.743	29.47 Picograms Standard Deviation 1.859	29.65 Picograms Standard Deviation 1.819
Part 1: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Day 2	29.28 Picograms Standard Deviation 1.811	29.51 Picograms Standard Deviation 1.834	29.63 Picograms Standard Deviation 1.823
Part 1: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Day 5	28.95 Picograms Standard Deviation 2.117	29.63 Picograms Standard Deviation 2.113	30.23 Picograms Standard Deviation 2.111
Part 1: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Day 7	29.61 Picograms Standard Deviation 1.924	29.61 Picograms Standard Deviation 1.853	29.34 Picograms Standard Deviation 1.735

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Baseline (Day -1)	28.51 Picograms Standard Deviation 2.271	28.62 Picograms Standard Deviation 2.379	—
Part 2: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Day 2	28.49 Picograms Standard Deviation 2.208	28.68 Picograms Standard Deviation 2.266	—
Part 2: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Day 5	28.84 Picograms Standard Deviation 1.508	28.32 Picograms Standard Deviation 2.810	—
Part 2: Absolute Values for Hematology Parameters: Erythrocytes Mean Corpuscular Hemoglobin Day 7	28.32 Picograms Standard Deviation 2.878	29.27 Picograms Standard Deviation 1.665	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameters: basophils, eosinophils, lymphocytes, monocytes, neutrophils, and platelets. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=21 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin Day 2	1.2 Grams per liter Standard Deviation 5.98	0.4 Grams per liter Standard Deviation 5.44	0.4 Grams per liter Standard Deviation 5.09
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin Day 5	0.5 Grams per liter Standard Deviation 4.46	-2.7 Grams per liter Standard Deviation 4.59	-1.3 Grams per liter Standard Deviation 5.01
Part 1: Change From Baseline in Hematology Parameter: Hemoglobin Day 7	-1.8 Grams per liter Standard Deviation 3.16	-3.2 Grams per liter Standard Deviation 7.57	0.0 Grams per liter Standard Deviation 5.10

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed

Blood samples were collected to analyze the hematology parameter: hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin Day 2	1.4 Grams per liter Standard Deviation 4.86	2.2 Grams per liter Standard Deviation 4.66	—
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin Day 5	-1.4 Grams per liter Standard Deviation 4.00	1.2 Grams per liter Standard Deviation 5.52	—
Part 2: Change From Baseline in Hematology Parameter: Hemoglobin Day 7	-1.2 Grams per liter Standard Deviation 4.35	1.7 Grams per liter Standard Deviation 3.84	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=21 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 2	-0.06 Femtoliter Standard Deviation 0.576	0.18 Femtoliter Standard Deviation 0.658	0.05 Femtoliter Standard Deviation 0.664
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 5	0.32 Femtoliter Standard Deviation 0.615	0.42 Femtoliter Standard Deviation 0.611	0.13 Femtoliter Standard Deviation 0.423
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 7	-0.58 Femtoliter Standard Deviation 0.456	0.10 Femtoliter Standard Deviation 0.663	-0.09 Femtoliter Standard Deviation 0.780

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular volume. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 2	-0.05 Femtoliter Standard Deviation 0.629	-0.16 Femtoliter Standard Deviation 0.444	—
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 5	-0.31 Femtoliter Standard Deviation 0.479	0.13 Femtoliter Standard Deviation 0.552	—
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Volume Day 7	-0.11 Femtoliter Standard Deviation 0.992	-0.13 Femtoliter Standard Deviation 0.418	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=21 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Day 2	0.052 10^12 cells per liter Standard Deviation 0.1937	0.005 10^12 cells per liter Standard Deviation 0.1651	0.014 10^12 cells per liter Standard Deviation 0.1672
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Day 5	0.020 10^12 cells per liter Standard Deviation 0.1642	-0.097 10^12 cells per liter Standard Deviation 0.1592	-0.062 10^12 cells per liter Standard Deviation 0.1297
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Day 7	-0.043 10^12 cells per liter Standard Deviation 0.1286	-0.115 10^12 cells per liter Standard Deviation 0.2308	0.010 10^12 cells per liter Standard Deviation 0.2011

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Day 2	0.034 10^12 cells per liter Standard Deviation 0.1628	0.061 10^12 cells per liter Standard Deviation 0.1886	—
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Day 5	-0.024 10^12 cells per liter Standard Deviation 0.1464	0.027 10^12 cells per liter Standard Deviation 0.2285	—
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Day 7	-0.077 10^12 cells per liter Standard Deviation 0.1875	-0.003 10^12 cells per liter Standard Deviation 0.1151	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=21 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Hematology Parameter: Hematocrit Day 2	0.0042 Proportion of red blood cells in blood Standard Deviation 0.01656	0.0013 Proportion of red blood cells in blood Standard Deviation 0.01405	0.0017 Proportion of red blood cells in blood Standard Deviation 0.01477
Part 1: Change From Baseline in Hematology Parameter: Hematocrit Day 5	0.0027 Proportion of red blood cells in blood Standard Deviation 0.01253	-0.0067 Proportion of red blood cells in blood Standard Deviation 0.01369	-0.0048 Proportion of red blood cells in blood Standard Deviation 0.01148
Part 1: Change From Baseline in Hematology Parameter: Hematocrit Day 7	-0.0066 Proportion of red blood cells in blood Standard Deviation 0.01184	-0.0092 Proportion of red blood cells in blood Standard Deviation 0.01971	0.0011 Proportion of red blood cells in blood Standard Deviation 0.01930

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameters: hemotocrit. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Hematology Parameter: Hematocrit Day 2	0.0029 Proportion of red blood cells in blood Standard Deviation 0.01474	0.0047 Proportion of red blood cells in blood Standard Deviation 0.01576	—
Part 2: Change From Baseline in Hematology Parameter: Hematocrit Day 5	-0.0038 Proportion of red blood cells in blood Standard Deviation 0.01403	0.0040 Proportion of red blood cells in blood Standard Deviation 0.02060	—
Part 2: Change From Baseline in Hematology Parameter: Hematocrit Day 7	-0.0074 Proportion of red blood cells in blood Standard Deviation 0.01795	-0.0007 Proportion of red blood cells in blood Standard Deviation 0.01093	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=21 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 2	-0.02 Picograms Standard Deviation 0.319	0.04 Picograms Standard Deviation 0.368	-0.02 Picograms Standard Deviation 0.233
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 5	0.05 Picograms Standard Deviation 0.138	0.07 Picograms Standard Deviation 0.280	0.17 Picograms Standard Deviation 0.301
Part 1: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 7	-0.05 Picograms Standard Deviation 0.372	0.01 Picograms Standard Deviation 0.423	-0.16 Picograms Standard Deviation 0.320

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the hematology parameter: erythrocytes mean corpuscular hemoglobin. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 2	0.07 Picograms Standard Deviation 0.451	0.06 Picograms Standard Deviation 0.463	—
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 5	-0.13 Picograms Standard Deviation 0.255	0.00 Picograms Standard Deviation 0.387	—
Part 2: Change From Baseline in Hematology Parameter: Erythrocytes Mean Corpuscular Hemoglobin Day 7	0.21 Picograms Standard Deviation 0.483	0.34 Picograms Standard Deviation 0.445	—

SECONDARY outcome

Timeframe: Baseline (Day -1), and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1), and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: serum lipase and serum amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Baseline (Day -1)	32.5 Units per Liter Standard Deviation 12.77	34.6 Units per Liter Standard Deviation 17.45	31.1 Units per Liter Standard Deviation 13.95
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Day 2	32.1 Units per Liter Standard Deviation 13.07	40.4 Units per Liter Standard Deviation 27.76	34.2 Units per Liter Standard Deviation 13.50
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Day 5	34.3 Units per Liter Standard Deviation 15.08	40.2 Units per Liter Standard Deviation 19.87	27.7 Units per Liter Standard Deviation 5.61
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Day 7	33.1 Units per Liter Standard Deviation 17.23	28.8 Units per Liter Standard Deviation 11.77	35.0 Units per Liter Standard Deviation 17.18
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Baseline (Day -1)	54.9 Units per Liter Standard Deviation 13.67	58.9 Units per Liter Standard Deviation 16.72	58.4 Units per Liter Standard Deviation 14.51
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Day 2	58.9 Units per Liter Standard Deviation 15.47	62.8 Units per Liter Standard Deviation 18.88	61.7 Units per Liter Standard Deviation 16.92
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Day 5	63.3 Units per Liter Standard Deviation 9.91	55.2 Units per Liter Standard Deviation 15.47	62.2 Units per Liter Standard Deviation 23.16
Part 1: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Day 7	62.0 Units per Liter Standard Deviation 19.18	62.2 Units per Liter Standard Deviation 14.71	56.2 Units per Liter Standard Deviation 13.57

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: serum lipase, serum amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Baseline (Day -1)	58.7 Units per Liter Standard Deviation 17.33	56.7 Units per Liter Standard Deviation 15.19	—
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Day 2	58.3 Units per Liter Standard Deviation 17.08	58.8 Units per Liter Standard Deviation 15.21	—
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Day 5	53.9 Units per Liter Standard Deviation 16.40	62.7 Units per Liter Standard Deviation 14.06	—
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum amylase, Day 7	63.3 Units per Liter Standard Deviation 15.98	51.7 Units per Liter Standard Deviation 14.27	—
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Baseline (Day -1)	32.1 Units per Liter Standard Deviation 11.73	30.2 Units per Liter Standard Deviation 10.22	—
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Day 2	30.5 Units per Liter Standard Deviation 11.60	30.4 Units per Liter Standard Deviation 11.12	—
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Day 5	28.6 Units per Liter Standard Deviation 19.28	40.3 Units per Liter Standard Deviation 15.17	—
Part 2: Absolute Values for Chemistry Parameters: Serum Lipase, Serum Amylase Serum lipase, Day 7	35.0 Units per Liter Standard Deviation 6.22	25.2 Units per Liter Standard Deviation 12.59	—

SECONDARY outcome

Timeframe: Baseline (Day -1), and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 2	44.6 Grams per liter Standard Deviation 2.61	44.5 Grams per liter Standard Deviation 2.29	44.5 Grams per liter Standard Deviation 2.46
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Baseline (Day -1)	43.8 Grams per liter Standard Deviation 2.91	43.8 Grams per liter Standard Deviation 3.12	43.8 Grams per liter Standard Deviation 2.38
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 5	43.8 Grams per liter Standard Deviation 2.23	43.8 Grams per liter Standard Deviation 2.32	43.2 Grams per liter Standard Deviation 4.12
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 7	43.6 Grams per liter Standard Deviation 2.66	43.9 Grams per liter Standard Deviation 2.22	45.3 Grams per liter Standard Deviation 2.16
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Baseline (Day -1)	26.4 Grams per liter Standard Deviation 4.04	27.0 Grams per liter Standard Deviation 3.25	26.0 Grams per liter Standard Deviation 3.63
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 2	27.3 Grams per liter Standard Deviation 3.85	27.4 Grams per liter Standard Deviation 3.72	27.1 Grams per liter Standard Deviation 4.51
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 5	26.0 Grams per liter Standard Deviation 2.61	28.0 Grams per liter Standard Deviation 3.52	26.2 Grams per liter Standard Deviation 3.37
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 7	27.1 Grams per liter Standard Deviation 3.78	25.8 Grams per liter Standard Deviation 3.60	25.9 Grams per liter Standard Deviation 4.31
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Baseline (Day -1)	70.1 Grams per liter Standard Deviation 5.10	70.8 Grams per liter Standard Deviation 4.12	69.7 Grams per liter Standard Deviation 4.46
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 2	71.9 Grams per liter Standard Deviation 4.86	71.9 Grams per liter Standard Deviation 4.03	71.6 Grams per liter Standard Deviation 5.60
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 5	69.8 Grams per liter Standard Deviation 1.94	71.8 Grams per liter Standard Deviation 4.71	69.3 Grams per liter Standard Deviation 5.28
Part 1: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 7	70.7 Grams per liter Standard Deviation 4.90	69.8 Grams per liter Standard Deviation 4.17	71.2 Grams per liter Standard Deviation 4.71

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Baseline (Day -1)	42.9 Grams per liter Standard Deviation 3.72	43.1 Grams per liter Standard Deviation 3.40	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 2	43.3 Grams per liter Standard Deviation 2.91	43.2 Grams per liter Standard Deviation 3.26	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 5	44.4 Grams per liter Standard Deviation 2.56	44.9 Grams per liter Standard Deviation 4.04	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 7	43.3 Grams per liter Standard Deviation 4.33	43.2 Grams per liter Standard Deviation 2.39	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Baseline (Day -1)	28.0 Grams per liter Standard Deviation 3.39	27.2 Grams per liter Standard Deviation 3.64	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 2	28.5 Grams per liter Standard Deviation 3.27	28.1 Grams per liter Standard Deviation 3.47	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 5	27.1 Grams per liter Standard Deviation 3.94	30.4 Grams per liter Standard Deviation 3.78	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 7	28.4 Grams per liter Standard Deviation 3.64	25.9 Grams per liter Standard Deviation 3.48	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Baseline (Day -1)	70.9 Grams per liter Standard Deviation 4.83	70.3 Grams per liter Standard Deviation 4.69	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 2	71.8 Grams per liter Standard Deviation 3.60	71.3 Grams per liter Standard Deviation 4.60	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 5	71.5 Grams per liter Standard Deviation 3.96	75.3 Grams per liter Standard Deviation 5.00	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 7	71.8 Grams per liter Standard Deviation 6.04	69.1 Grams per liter Standard Deviation 4.23	—

SECONDARY outcome

Timeframe: Baseline (Day -1), and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: ALT, ALP, AST, GGT, LDH, CK. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: calcium, CO2, chloride, glucose, potassium, sodium, urea nitrogen, phosphorus, triglycerides, cholesterol, and anion gap. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: lipase and amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Lipase, Day 2	-0.4 Units per Liter Standard Deviation 5.21	5.8 Units per Liter Standard Deviation 13.57	3.2 Units per Liter Standard Deviation 10.59
Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Lipase, Day 5	3.3 Units per Liter Standard Deviation 3.33	1.3 Units per Liter Standard Deviation 3.98	2.0 Units per Liter Standard Deviation 9.92
Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Lipase, Day 7	4.5 Units per Liter Standard Deviation 15.61	-3.6 Units per Liter Standard Deviation 19.59	2.1 Units per Liter Standard Deviation 5.49
Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Amylase, Day 2	4.0 Units per Liter Standard Deviation 5.54	3.9 Units per Liter Standard Deviation 5.21	3.3 Units per Liter Standard Deviation 8.70
Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Amylase, Day 5	5.5 Units per Liter Standard Deviation 4.23	0.5 Units per Liter Standard Deviation 4.32	-1.2 Units per Liter Standard Deviation 7.94
Part 1: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Amylase, Day 7	5.0 Units per Liter Standard Deviation 9.08	-0.7 Units per Liter Standard Deviation 10.27	3.5 Units per Liter Standard Deviation 9.23

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: lipase and amylase. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Lipase, Day 2	-1.6 Units per Liter Standard Deviation 5.77	0.3 Units per Liter Standard Deviation 3.51	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Lipase, Day 5	2.3 Units per Liter Standard Deviation 20.10	5.3 Units per Liter Standard Deviation 13.17	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Lipase, Day 7	-2.2 Units per Liter Standard Deviation 8.77	-0.1 Units per Liter Standard Deviation 4.65	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Amylase, Day 2	0.8 Units per Liter Standard Deviation 4.11	2.1 Units per Liter Standard Deviation 3.83	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Amylase, Day 5	0.8 Units per Liter Standard Deviation 7.42	-0.7 Units per Liter Standard Deviation 6.84	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Lipase and Amylase Amylase, Day 7	-0.3 Units per Liter Standard Deviation 6.28	1.6 Units per Liter Standard Deviation 4.39	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 2	0.8 Grams per liter Standard Deviation 2.65	0.7 Grams per liter Standard Deviation 2.08	0.7 Grams per liter Standard Deviation 1.49
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 5	-0.8 Grams per liter Standard Deviation 1.72	0.2 Grams per liter Standard Deviation 2.32	-0.2 Grams per liter Standard Deviation 2.32
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 7	0.2 Grams per liter Standard Deviation 2.14	0.0 Grams per liter Standard Deviation 2.68	1.3 Grams per liter Standard Deviation 1.49
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 2	1.0 Grams per liter Standard Deviation 2.44	0.4 Grams per liter Standard Deviation 1.80	1.2 Grams per liter Standard Deviation 2.23
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 5	0.2 Grams per liter Standard Deviation 2.40	0.2 Grams per liter Standard Deviation 1.17	1.0 Grams per liter Standard Deviation 2.10
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 7	0.0 Grams per liter Standard Deviation 1.67	-0.5 Grams per liter Standard Deviation 2.33	0.6 Grams per liter Standard Deviation 1.84
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 2	1.8 Grams per liter Standard Deviation 4.69	1.1 Grams per liter Standard Deviation 3.65	1.9 Grams per liter Standard Deviation 3.54
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 5	-0.7 Grams per liter Standard Deviation 2.80	0.3 Grams per liter Standard Deviation 2.58	0.8 Grams per liter Standard Deviation 3.13
Part 1: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 7	0.2 Grams per liter Standard Deviation 3.49	-0.5 Grams per liter Standard Deviation 4.56	1.9 Grams per liter Standard Deviation 2.81

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: albumin, globulin and protein. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 2	0.6 Grams per liter Standard Deviation 2.78	0.2 Grams per liter Standard Deviation 2.18	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 5	0.9 Grams per liter Standard Deviation 3.00	1.6 Grams per liter Standard Deviation 4.36	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Albumin, Day 7	0.9 Grams per liter Standard Deviation 2.47	0.4 Grams per liter Standard Deviation 3.17	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 2	0.3 Grams per liter Standard Deviation 1.98	0.8 Grams per liter Standard Deviation 2.28	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 5	0.8 Grams per liter Standard Deviation 1.67	2.0 Grams per liter Standard Deviation 2.78	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Globulin, Day 7	-1.0 Grams per liter Standard Deviation 3.08	-0.1 Grams per liter Standard Deviation 2.42	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 2	0.9 Grams per liter Standard Deviation 3.95	1.0 Grams per liter Standard Deviation 3.33	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 5	1.6 Grams per liter Standard Deviation 3.85	3.6 Grams per liter Standard Deviation 6.27	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Albumin, Globulin and Protein Protein, Day 7	-0.1 Grams per liter Standard Deviation 4.04	0.3 Grams per liter Standard Deviation 4.58	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 2	8.31 Micromoles per liter Standard Deviation 4.422	7.12 Micromoles per liter Standard Deviation 5.636	6.15 Micromoles per liter Standard Deviation 4.228
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 5	3.10 Micromoles per liter Standard Deviation 2.440	3.38 Micromoles per liter Standard Deviation 3.026	1.92 Micromoles per liter Standard Deviation 2.671
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 7	2.18 Micromoles per liter Standard Deviation 5.799	0.97 Micromoles per liter Standard Deviation 5.027	1.34 Micromoles per liter Standard Deviation 6.215
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 2	-0.12 Micromoles per liter Standard Deviation 0.267	-0.06 Micromoles per liter Standard Deviation 0.329	-0.01 Micromoles per liter Standard Deviation 0.324
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 5	-0.20 Micromoles per liter Standard Deviation 0.261	0.02 Micromoles per liter Standard Deviation 0.354	0.35 Micromoles per liter Standard Deviation 0.138
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 7	-0.03 Micromoles per liter Standard Deviation 0.390	-0.11 Micromoles per liter Standard Deviation 0.330	-0.11 Micromoles per liter Standard Deviation 0.502
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 2	-0.68 Micromoles per liter Standard Deviation 1.327	-0.39 Micromoles per liter Standard Deviation 1.742	-0.21 Micromoles per liter Standard Deviation 1.236
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 5	-1.85 Micromoles per liter Standard Deviation 1.958	-1.12 Micromoles per liter Standard Deviation 1.306	0.55 Micromoles per liter Standard Deviation 0.602
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 7	0.10 Micromoles per liter Standard Deviation 1.638	-1.06 Micromoles per liter Standard Deviation 1.340	-1.40 Micromoles per liter Standard Deviation 2.078
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 2	-7.0 Micromoles per liter Standard Deviation 17.31	-7.9 Micromoles per liter Standard Deviation 15.31	-4.2 Micromoles per liter Standard Deviation 21.77
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 5	-11.7 Micromoles per liter Standard Deviation 8.36	-7.0 Micromoles per liter Standard Deviation 17.15	6.7 Micromoles per liter Standard Deviation 30.59
Part 1: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 7	-6.4 Micromoles per liter Standard Deviation 28.61	-6.8 Micromoles per liter Standard Deviation 13.36	2.3 Micromoles per liter Standard Deviation 20.74

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Blood samples were collected to analyze the chemistry parameters: Creatinine, direct bilirubin, bilirubin, and urate. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 2	7.73 Micromoles per liter Standard Deviation 4.766	6.97 Micromoles per liter Standard Deviation 5.419	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 5	3.54 Micromoles per liter Standard Deviation 6.065	1.28 Micromoles per liter Standard Deviation 6.361	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 7	2.16 Micromoles per liter Standard Deviation 3.830	-0.98 Micromoles per liter Standard Deviation 3.061	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 2	0.07 Micromoles per liter Standard Deviation 0.328	0.04 Micromoles per liter Standard Deviation 0.405	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 5	0.13 Micromoles per liter Standard Deviation 0.212	0.37 Micromoles per liter Standard Deviation 0.374	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 7	-0.04 Micromoles per liter Standard Deviation 0.300	-0.12 Micromoles per liter Standard Deviation 0.307	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 2	0.02 Micromoles per liter Standard Deviation 1.518	0.31 Micromoles per liter Standard Deviation 1.101	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 5	-0.41 Micromoles per liter Standard Deviation 1.635	1.93 Micromoles per liter Standard Deviation 2.272	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 7	-0.78 Micromoles per liter Standard Deviation 2.499	-0.08 Micromoles per liter Standard Deviation 1.358	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 2	-12.4 Micromoles per liter Standard Deviation 19.25	2.6 Micromoles per liter Standard Deviation 15.74	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 5	-5.9 Micromoles per liter Standard Deviation 12.97	-2.0 Micromoles per liter Standard Deviation 13.42	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 7	-6.0 Micromoles per liter Standard Deviation 19.21	-18.0 Micromoles per liter Standard Deviation 22.32	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity Baseline (Day -1)	1.0138 Ratio Standard Deviation 0.00654	1.0168 Ratio Standard Deviation 0.00685	1.0153 Ratio Standard Deviation 0.00693
Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity Day 2	1.0137 Ratio Standard Deviation 0.00683	1.0150 Ratio Standard Deviation 0.00766	1.0151 Ratio Standard Deviation 0.00763
Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity Day 5	1.0143 Ratio Standard Deviation 0.00543	1.0197 Ratio Standard Deviation 0.00638	1.0197 Ratio Standard Deviation 0.00799
Part 1: Absolute Values for Urinalysis Parameter: Specific Gravity Day 7	1.0202 Ratio Standard Deviation 0.00569	1.0159 Ratio Standard Deviation 0.00760	1.0160 Ratio Standard Deviation 0.00733

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2 : Absolute Values for Urinalysis Parameter: Specific Gravity Baseline (Day -1)	1.0146 Ratio Standard Deviation 0.00742	1.0164 Ratio Standard Deviation 0.00834	—
Part 2 : Absolute Values for Urinalysis Parameter: Specific Gravity Day 2	1.0157 Ratio Standard Deviation 0.00778	1.0182 Ratio Standard Deviation 0.00906	—
Part 2 : Absolute Values for Urinalysis Parameter: Specific Gravity Day 5	1.0123 Ratio Standard Deviation 0.00715	1.0142 Ratio Standard Deviation 0.01284	—
Part 2 : Absolute Values for Urinalysis Parameter: Specific Gravity Day 7	1.0161 Ratio Standard Deviation 0.01129	1.0144 Ratio Standard Deviation 0.00735	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Urinalysis Parameters: Potential of Hydrogen (pH) Baseline (Day -1)	6.18 pH Standard Deviation 0.733	5.95 pH Standard Deviation 0.631	5.88 pH Standard Deviation 0.582
Part 1: Absolute Values for Urinalysis Parameters: Potential of Hydrogen (pH) Day 2	6.16 pH Standard Deviation 0.585	6.12 pH Standard Deviation 0.723	6.20 pH Standard Deviation 0.785
Part 1: Absolute Values for Urinalysis Parameters: Potential of Hydrogen (pH) Day 5	5.83 pH Standard Deviation 0.408	5.83 pH Standard Deviation 0.258	5.75 pH Standard Deviation 0.274
Part 1: Absolute Values for Urinalysis Parameters: Potential of Hydrogen (pH) Day 7	5.82 pH Standard Deviation 0.603	5.81 pH Standard Deviation 0.596	6.15 pH Standard Deviation 0.914

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen Baseline (Day -1)	6.12 pH Standard Deviation 0.574	6.08 pH Standard Deviation 0.354	—
Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen Day 2	6.12 pH Standard Deviation 0.452	6.17 pH Standard Deviation 0.454	—
Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen Day 5	6.13 pH Standard Deviation 0.518	6.28 pH Standard Deviation 0.565	—
Part 1: Absolute Values for Urinalysis Parameter: Potential of Hydrogen Day 7	6.17 pH Standard Deviation 0.433	5.94 pH Standard Deviation 0.464	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including glucose by dipstick. Urinalysis included dipstick urine test which was used to screen for glucose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Urinalysis Dipstick Results: Glucose Day 5, Negative	6 Participants	6 Participants	6 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Glucose Day 7, Negative	11 Participants	13 Participants	10 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Glucose Baseline (Day -1), Negative	22 Participants	21 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Glucose Day 2, Negative	22 Participants	21 Participants	20 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including glucose by dipstick. Urinalysis included dipstick urine test which was used to screen for glucose. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine glucose can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Urinalysis Dipstick Results: Glucose Baseline (Day -1), Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Glucose Day 2, Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Glucose Day 5, Negative	8 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Glucose Day 7, Negative	9 Participants	9 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including protein by dipstick. Urinalysis included dipstick urine test which was used to screen for protein. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine protein can be read as negative, and trace in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Urinalysis Dipstick Results: Protein Baseline (Day -1), Negative	22 Participants	21 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Protein Day 2, Negative	22 Participants	21 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Protein Day 5, Negative	6 Participants	6 Participants	6 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Protein Day 7, Trace	1 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Protein Day 7, Negative	10 Participants	13 Participants	10 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including protein by dipstick. Urinalysis included dipstick urine test which was used to screen for protein. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine protein can be read as negative, and trace in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Urinalysis Dipstick Results: Protein Day 7, Trace	1 Participants	0 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Protein Baseline (Day -1), Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Protein Day 2, Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Protein Day 5, Negative	8 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Protein Day 7, Negative	8 Participants	9 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including occult blood by dipstick. Urinalysis included dipstick urine test which was used to screen for occult blood. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine occult blood can be read as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Baseline (Day -1), Negative	20 Participants	18 Participants	18 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Baseline (Day -1), Trace	1 Participants	2 Participants	2 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Baseline (Day -1), 2+	1 Participants	1 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 2, Negative	19 Participants	17 Participants	18 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 2, Trace	2 Participants	3 Participants	1 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 2, 1+	0 Participants	0 Participants	1 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 2, 2+	1 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 2, 3+	0 Participants	1 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 5, Negative	4 Participants	5 Participants	6 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 5, 1+	1 Participants	1 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 5, 2+	1 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 7, Negative	10 Participants	11 Participants	9 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 7, Trace	1 Participants	2 Participants	1 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including occult blood by dipstick. Urinalysis included dipstick urine test which was used to screen for occult blood. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine occult blood can be read as negative, trace, 1+, 2+, 3+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Baseline (Day -1), Trace	1 Participants	0 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Baseline (Day -1), 1+	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Baseline (Day -1), 2+	1 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 2, Negative	17 Participants	17 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Baseline (Day -1), Negative	15 Participants	16 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 2, 1+	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 5, Negative	8 Participants	8 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 5, Trace	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 7, Negative	7 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 7, 1+	1 Participants	0 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Occult Blood Day 7, 2+	1 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including ketones by dipstick. Urinalysis included dipstick urine test which was used to screen for ketones. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine ketones can be read as negative, trace, 2+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Baseline (Day -1), Negative	22 Participants	20 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Baseline (Day -1), Trace	0 Participants	1 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Day 2, Negative	21 Participants	21 Participants	19 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Day 2, Trace	1 Participants	0 Participants	1 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Day 5, Negative	6 Participants	6 Participants	5 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Day 5, 2+	0 Participants	0 Participants	1 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Day 7, Negative	10 Participants	13 Participants	10 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Ketones Day 7, Trace	1 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including ketones by dipstick. Urinalysis included dipstick urine test which was used to screen for ketones. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine ketones can be read as negative, trace, 1+, 2+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Baseline (Day -1), Negative	17 Participants	17 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Baseline (Day -1), Trace	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Day 2, Negative	17 Participants	17 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Day 2, 1+	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Day 5, Negative	8 Participants	7 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Day 5, Trace	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Day 5, 2+	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Day 7, Negative	8 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Ketones Day 7, Trace	1 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including bilirubin and nitrite by dipstick. Urinalysis included dipstick urine test which was used to screen for bilirubin and nitrite. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine bilirubin and nitrite can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Baseline (Day -1), Negative	22 Participants	21 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Day 2, Negative	22 Participants	21 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Day 5, Negative	6 Participants	6 Participants	6 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Day 7, Negative	11 Participants	13 Participants	10 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Baseline (Day -1), Negative	22 Participants	21 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Day 2, Negative	22 Participants	21 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Day 5, Negative	6 Participants	6 Participants	6 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Day 7, Negative	11 Participants	13 Participants	10 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including bilirubin and nitrite by dipstick. Urinalysis included dipstick urine test which was used to screen for bilirubin and nitrite. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine bilirubin and nitrite can be read as negative in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Baseline (Day -1), Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Day 2, Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Day 5, Negative	8 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Bilirubin, Day 7, Negative	9 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Baseline (Day -1), Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Day 2, Negative	17 Participants	18 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Day 5, Negative	8 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Bilirubin and Nitrite Nitrite, Day 7, Negative	9 Participants	9 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including leukocyte esterase by dipstick. Urinalysis included dipstick urine test which was used to screen for leukocyte esterase. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine leukocyte esterase can be read as negative, trace, 1+ indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Baseline (Day -1), Negative	21 Participants	19 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Baseline (Day -1), Trace	1 Participants	2 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 2, Negative	22 Participants	19 Participants	20 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 2, 1+	0 Participants	2 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 5, Negative	6 Participants	6 Participants	5 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 5, 1+	0 Participants	0 Participants	1 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 7, Negative	9 Participants	12 Participants	10 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 7, Trace	2 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 7, 1+	0 Participants	1 Participants	0 Participants

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected at indicated time points to analyze parameters including leukocyte esterase by dipstick. Urinalysis included dipstick urine test which was used to screen for leukocyte esterase. The dipstick test gives results in a semi-quantitative manner, and results for urinalysis parameters of urine leukocyte esterase can be read as negative, trace indicating proportional concentrations in the urine sample. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Baseline (Day -1), Negative	17 Participants	17 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Baseline (Day -1), Trace	0 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 2, Negative	15 Participants	17 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 2, Trace	2 Participants	1 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 5, Negative	8 Participants	9 Participants	—
Part 2: Number of Participants With Urinalysis Dipstick Results: Leukocyte Esterase Day 7, Negative	9 Participants	9 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 2	0.0000 Ratio Standard Deviation 0.00662	-0.0017 Ratio Standard Deviation 0.00770	-0.0002 Ratio Standard Deviation 0.00738
Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 5	0.0033 Ratio Standard Deviation 0.00505	0.0043 Ratio Standard Deviation 0.00524	0.0030 Ratio Standard Deviation 0.00329
Part 1: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 7	0.0056 Ratio Standard Deviation 0.00877	-0.0014 Ratio Standard Deviation 0.00957	0.0010 Ratio Standard Deviation 0.00794

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: specific gravity. Urine specific gravity is a measure of the concentration of solutes in the urine and provides information on the kidney's ability to concentrate urine. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 2	0.0011 Ratio Standard Deviation 0.00679	0.0018 Ratio Standard Deviation 0.00899	—
Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 5	-0.0005 Ratio Standard Deviation 0.00447	-0.0019 Ratio Standard Deviation 0.01156	—
Part 2: Change From Baseline in Urinalysis Parameter: Specific Gravity Day 7	-0.0001 Ratio Standard Deviation 0.00551	-0.0022 Ratio Standard Deviation 0.00748	—

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visit, prior to the first study drug administration in each treatment period. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen Day 2	-0.02 pH Standard Deviation 0.545	0.17 pH Standard Deviation 0.796	0.33 pH Standard Deviation 0.520
Part 1: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen Day 5	-0.58 pH Standard Deviation 0.665	-0.08 pH Standard Deviation 0.585	-0.08 pH Standard Deviation 0.204
Part 1: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen Day 7	-0.45 pH Standard Deviation 0.416	-0.31 pH Standard Deviation 0.723	0.15 pH Standard Deviation 0.412

SECONDARY outcome

Timeframe: Baseline (Day -1) and Days 2, 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urinalysis parameter: pH. Urine pH is an acid-base measurement. pH is measured on a numeric scale ranging from 0 to 14; values on the scale refer to the degree of alkalinity or acidity. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen Day 5	0.13 pH Standard Deviation 0.354	0.11 pH Standard Deviation 0.333	—
Part 2: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen Day 7	-0.06 pH Standard Deviation 0.464	-0.06 pH Standard Deviation 0.635	—
Part 2: Change From Baseline for Urinalysis Parameter: Potential of Hydrogen Day 2	0.00 pH Standard Deviation 0.586	0.08 pH Standard Deviation 0.393	—

SECONDARY outcome

Timeframe: Up to Day 17

Population: Safety Population

Urine samples were collected to analyze the urine parameter: glucose. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 1	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 2	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 3	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 4	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 9

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urine parameter: glucose. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 1	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 2	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 3	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Glucose Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 4	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Up to Day 17

Population: Safety Population

Urine samples were collected to analyze the urine parameter: protein. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 1	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 2	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 3	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 4	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 9

Population: Safety Population

Urine samples were collected to analyze the urine parameter: protein. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 1	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 2	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 3	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Protein Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 4	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Up to Day 17

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Urine samples were collected to analyze the urine parameter: erythrocytes. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=8 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=7 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=4 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 1	1 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 2	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 3	0 Participants	0 Participants	0 Participants
Part 1: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 4	0 Participants	0 Participants	0 Participants

SECONDARY outcome

Timeframe: Up to Day 9

Population: Safety Population

Urine samples were collected to analyze the urine parameter: erythrocytes. Urinalysis parameters were graded according to Division of Acquired Immune Deficiency Syndrome (DAIDS) grading for severity of laboratory toxicities and clinical adverse events, version 2.1. The grades were grade 1 (mild), 2 (moderate), 3 (severe) and 4 (potentially life-threatening). Baseline was defined as the last assessment before the first dose of the study treatment. Only those urine parameters with maximum post-Baseline grade increase (Grade 1 to Grade 4) have been presented.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 1	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 2	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 3	0 Participants	0 Participants	—
Part 2: Number of Participants With Worst Case Urine Parameter: Erythrocytes Results by Maximum Grade Increase Post-Baseline Relative to Baseline Increase to Grade 4	0 Participants	0 Participants	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, and QTcF interval . Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) PR Interval, Baseline (Day1 pre-dose)	162.8 Milliseconds Standard Deviation 17.39	162.8 Milliseconds Standard Deviation 18.05	163.1 Milliseconds Standard Deviation 16.90
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) PR Interval, Day 1, 2 hours	159.0 Milliseconds Standard Deviation 18.13	158.0 Milliseconds Standard Deviation 17.16	157.7 Milliseconds Standard Deviation 17.78
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) PR Interval, Day 1, 4 hours	159.2 Milliseconds Standard Deviation 17.50	160.0 Milliseconds Standard Deviation 17.51	159.9 Milliseconds Standard Deviation 15.79
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) PR Interval, Day 1, 6 hours	160.4 Milliseconds Standard Deviation 18.70	158.2 Milliseconds Standard Deviation 18.10	160.1 Milliseconds Standard Deviation 16.87
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) PR Interval, Day 5	162.2 Milliseconds Standard Deviation 16.02	170.8 Milliseconds Standard Deviation 12.42	159.8 Milliseconds Standard Deviation 31.98
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QRS Duration, Baseline (Day 1)	92.0 Milliseconds Standard Deviation 7.09	93.1 Milliseconds Standard Deviation 7.83	93.4 Milliseconds Standard Deviation 8.61
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QRS Duration, Day 1, 2 hours	91.3 Milliseconds Standard Deviation 7.12	92.8 Milliseconds Standard Deviation 9.11	92.8 Milliseconds Standard Deviation 8.15
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QRS Duration, Day 1, 4 hours	90.0 Milliseconds Standard Deviation 8.16	91.5 Milliseconds Standard Deviation 8.18	91.7 Milliseconds Standard Deviation 9.04
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QRS Duration, Day 1, 6 hours	91.0 Milliseconds Standard Deviation 7.67	91.7 Milliseconds Standard Deviation 8.87	93.2 Milliseconds Standard Deviation 8.63
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QRS Duration, Day 5	92.3 Milliseconds Standard Deviation 4.93	94.2 Milliseconds Standard Deviation 6.24	94.8 Milliseconds Standard Deviation 9.99
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QT Interval, Baseline (Day 1)	397.0 Milliseconds Standard Deviation 26.26	393.1 Milliseconds Standard Deviation 29.10	394.2 Milliseconds Standard Deviation 24.66
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QT Interval, Day 1, 2 hours	381.1 Milliseconds Standard Deviation 24.29	375.0 Milliseconds Standard Deviation 24.49	375.6 Milliseconds Standard Deviation 19.77
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QT Interval, Day 1, 4 hours	391.2 Milliseconds Standard Deviation 26.27	385.0 Milliseconds Standard Deviation 23.31	386.4 Milliseconds Standard Deviation 21.34
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QT Interval, Day 1, 6 hours	387.8 Milliseconds Standard Deviation 21.90	379.3 Milliseconds Standard Deviation 23.66	382.2 Milliseconds Standard Deviation 20.88
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QT Interval, Day 5	389.5 Milliseconds Standard Deviation 18.32	374.8 Milliseconds Standard Deviation 29.13	400.5 Milliseconds Standard Deviation 9.01
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QTcF Interval, Baseline (Day 1)	404.3 Milliseconds Standard Deviation 17.15	400.7 Milliseconds Standard Deviation 19.60	403.7 Milliseconds Standard Deviation 14.85
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QTcF Interval, Day 1, 2 hours	397.5 Milliseconds Standard Deviation 18.03	393.1 Milliseconds Standard Deviation 19.20	397.0 Milliseconds Standard Deviation 15.11
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QTcF Interval, Day 1, 4 hours	399.1 Milliseconds Standard Deviation 19.40	396.5 Milliseconds Standard Deviation 399.3	399.3 Milliseconds Standard Deviation 17.85
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QTcF Interval, Day 1, 6 hours	401.8 Milliseconds Standard Deviation 17.12	398.4 Milliseconds Standard Deviation 19.80	399.0 Milliseconds Standard Deviation 16.65
Part 1: Absolute Values of Electrocardiogram (ECG) Parameters: PR Interval, QRS Duration, QT Interval and QT Interval Corrected by Fridericia's Formula (QTcF) QTcF Interval, Day 5	396.5 Milliseconds Standard Deviation 23.48	399.0 Milliseconds Standard Deviation 17.93	395.7 Milliseconds Standard Deviation 13.69

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, and Days 5, 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, and QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QTcF Interval, Day 7	395.3 Milliseconds Standard Deviation 12.11	381.1 Milliseconds Standard Deviation 9.78	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF PR Interval, Baseline (Day 1 pre-dose)	168.8 Milliseconds Standard Deviation 15.94	170.9 Milliseconds Standard Deviation 14.96	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF PR Interval, Day 1, 2 hours	160.6 Milliseconds Standard Deviation 14.92	167.0 Milliseconds Standard Deviation 14.71	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF PR Interval, Day 1, 4 hours	162.6 Milliseconds Standard Deviation 17.19	167.4 Milliseconds Standard Deviation 13.84	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF PR Interval, Day 1, 6 hours	162.2 Milliseconds Standard Deviation 15.23	160.9 Milliseconds Standard Deviation 14.18	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF PR Interval, Day 5	172.1 Milliseconds Standard Deviation 19.92	164.1 Milliseconds Standard Deviation 9.69	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF PR Interval, Day 7	167.1 Milliseconds Standard Deviation 9.09	176.2 Milliseconds Standard Deviation 18.97	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QRS Duration, Baseline (Day 1)	89.8 Milliseconds Standard Deviation 7.17	89.1 Milliseconds Standard Deviation 5.71	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QRS Duration, Day 1, 2 hours	88.8 Milliseconds Standard Deviation 6.87	87.9 Milliseconds Standard Deviation 5.56	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QRS Duration, Day 1, 4 hours	87.5 Milliseconds Standard Deviation 6.74	89.3 Milliseconds Standard Deviation 6.49	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QRS Duration, Day 1, 6 hours	87.5 Milliseconds Standard Deviation 6.50	89.7 Milliseconds Standard Deviation 7.11	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QRS Duration, Day 5	87.8 Milliseconds Standard Deviation 4.03	89.2 Milliseconds Standard Deviation 8.51	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QRS Duration, Day 7	89.9 Milliseconds Standard Deviation 6.83	88.8 Milliseconds Standard Deviation 3.15	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QT Interval, Baseline (Day 1)	382.8 Milliseconds Standard Deviation 16.73	383.6 Milliseconds Standard Deviation 18.49	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QT Interval, Day 1, 2 hours	367.0 Milliseconds Standard Deviation 15.73	385.2 Milliseconds Standard Deviation 18.67	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QT Interval, Day 1, 4 hours	373.4 Milliseconds Standard Deviation 11.37	391.8 Milliseconds Standard Deviation 16.57	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QT Interval, Day 1, 6 hours	372.9 Milliseconds Standard Deviation 16.48	367.8 Milliseconds Standard Deviation 15.07	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QT Interval, Day 5	367.8 Milliseconds Standard Deviation 13.94	385.2 Milliseconds Standard Deviation 25.34	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QT Interval, Day 7	382.6 Milliseconds Standard Deviation 17.92	378.2 Milliseconds Standard Deviation 14.66	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QTcF Interval, Baseline (Day 1)	393.3 Milliseconds Standard Deviation 11.84	390.9 Milliseconds Standard Deviation 13.13	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QTcF Interval, Day 1, 2 hours	387.2 Milliseconds Standard Deviation 12.56	390.3 Milliseconds Standard Deviation 16.98	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QTcF Interval, Day 1, 4 hours	388.8 Milliseconds Standard Deviation 11.52	392.3 Milliseconds Standard Deviation 14.99	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QTcF Interval, Day 1, 6 hours	389.4 Milliseconds Standard Deviation 11.52	390.2 Milliseconds Standard Deviation 13.13	—
Part 2: Absolute Values of ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF QTcF Interval, Day 5	388.6 Milliseconds Standard Deviation 7.63	395.3 Milliseconds Standard Deviation 14.71	—

SECONDARY outcome

Timeframe: Baseline (Day 1, Pre-dose), and Day 1: 2, 4, 6 hours, and Day 5

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 1, 2 hours	-3.8 Milliseconds Standard Deviation 10.19	-4.7 Milliseconds Standard Deviation 7.79	-5.5 Milliseconds Standard Deviation 11.16
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 1, 4 hours	-3.6 Milliseconds Standard Deviation 10.28	-2.8 Milliseconds Standard Deviation 6.31	-3.3 Milliseconds Standard Deviation 9.04
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 1, 6 hours	-2.5 Milliseconds Standard Deviation 9.65	-4.6 Milliseconds Standard Deviation 11.29	-3.0 Milliseconds Standard Deviation 10.31
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 5	2.8 Milliseconds Standard Deviation 9.13	-1.8 Milliseconds Standard Deviation 8.28	-6.0 Milliseconds Standard Deviation 9.44
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 1, 2 hours	-0.7 Milliseconds Standard Deviation 4.22	-0.4 Milliseconds Standard Deviation 4.60	-0.7 Milliseconds Standard Deviation 3.12
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 1, 4 hours	-2.0 Milliseconds Standard Deviation 4.40	-1.6 Milliseconds Standard Deviation 5.00	-1.7 Milliseconds Standard Deviation 3.54
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 1, 6 hours	-1.0 Milliseconds Standard Deviation 4.55	-1.4 Milliseconds Standard Deviation 3.99	-0.3 Milliseconds Standard Deviation 2.45
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 5	2.0 Milliseconds Standard Deviation 3.46	-1.3 Milliseconds Standard Deviation 4.97	-0.8 Milliseconds Standard Deviation 2.14
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 1, 2 hours	-15.8 Milliseconds Standard Deviation 11.54	-18.1 Milliseconds Standard Deviation 10.24	-18.6 Milliseconds Standard Deviation 11.71
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 1, 4 hours	-5.8 Milliseconds Standard Deviation 14.45	-8.1 Milliseconds Standard Deviation 13.18	-7.9 Milliseconds Standard Deviation 11.78
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 1, 6 hours	-9.1 Milliseconds Standard Deviation 12.89	-13.8 Milliseconds Standard Deviation 13.51	-12.0 Milliseconds Standard Deviation 13.81
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 5	0.8 Milliseconds Standard Deviation 14.27	-14.8 Milliseconds Standard Deviation 19.54	-14.5 Milliseconds Standard Deviation 9.85
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 1, 2 hours	-6.8 Milliseconds Standard Deviation 7.36	-7.6 Milliseconds Standard Deviation 6.58	-6.8 Milliseconds Standard Deviation 6.32
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 1, 4 hours	-5.1 Milliseconds Standard Deviation 9.07	-4.2 Milliseconds Standard Deviation 8.58	-4.5 Milliseconds Standard Deviation 6.88
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 1, 6 hours	-2.5 Milliseconds Standard Deviation 8.72	-2.2 Milliseconds Standard Deviation 9.87	-4.7 Milliseconds Standard Deviation 7.34
Part 1: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 5	-6.0 Milliseconds Standard Deviation 14.04	-2.3 Milliseconds Standard Deviation 14.31	-5.8 Milliseconds Standard Deviation 8.16

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 2, 4, 6 hours, Days 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Twelve lead ECGs were obtained to measure PR interval, QRS duration, QT interval, QTcF interval. Twelve lead ECGs were performed with the participant in a supine position after a rest of at least 10 minutes. Baseline was defined as the average of the triplicate pre-dose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 1, 2 hours	-8.1 Milliseconds Standard Deviation 10.19	-3.9 Milliseconds Standard Deviation 8.27	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 1, 4 hours	-6.1 Milliseconds Standard Deviation 12.06	-3.4 Milliseconds Standard Deviation 9.73	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 1, 6 hours	-6.5 Milliseconds Standard Deviation 10.71	-9.9 Milliseconds Standard Deviation 12.21	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 5	-4.5 Milliseconds Standard Deviation 10.94	-4.8 Milliseconds Standard Deviation 8.84	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval PR Interval, Day 7	5.3 Milliseconds Standard Deviation 7.89	3.3 Milliseconds Standard Deviation 11.88	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 1, 2 hours	-1.0 Milliseconds Standard Deviation 5.14	-1.2 Milliseconds Standard Deviation 2.56	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 1, 4 hours	-2.3 Milliseconds Standard Deviation 5.39	0.2 Milliseconds Standard Deviation 2.21	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration Day 1, 6 hours	-2.2 Milliseconds Standard Deviation 4.97	0.6 Milliseconds Standard Deviation 2.75	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 5	-3.8 Milliseconds Standard Deviation 7.74	0.0 Milliseconds Standard Deviation 2.74	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QRS Duration, Day 7	1.7 Milliseconds Standard Deviation 3.12	-0.2 Milliseconds Standard Deviation 3.93	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 1, 2 hours	-15.8 Milliseconds Standard Deviation 13.03	1.6 Milliseconds Standard Deviation 11.34	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 1, 4 hours	-9.5 Milliseconds Standard Deviation 13.61	8.2 Milliseconds Standard Deviation 10.80	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 1, 6 hours	-9.9 Milliseconds Standard Deviation 14.35	-15.7 Milliseconds Standard Deviation 10.87	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 5	-16.0 Milliseconds Standard Deviation 17.47	-2.3 Milliseconds Standard Deviation 19.62	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QT Interval, Day 7	0.6 Milliseconds Standard Deviation 8.03	-1.3 Milliseconds Standard Deviation 16.72	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 1, 2 hours	-6.1 Milliseconds Standard Deviation 11.76	-0.6 Milliseconds Standard Deviation 8.47	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 1, 4 hours	-4.5 Milliseconds Standard Deviation 8.52	1.4 Milliseconds Standard Deviation 7.88	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 1, 6 hours	-3.9 Milliseconds Standard Deviation 5.96	-0.8 Milliseconds Standard Deviation 8.05	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 5	-0.5 Milliseconds Standard Deviation 6.26	0.2 Milliseconds Standard Deviation 9.56	—
Part 2: Change From Baseline in ECG Parameters: PR Interval, QRS Duration, QT Interval and QTcF Interval QTcF Interval, Day 7	-1.7 Milliseconds Standard Deviation 6.48	-5.7 Milliseconds Standard Deviation 11.38	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline is defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP, Baseline (Day 1)	61.5 Millimeters of mercury Standard Deviation 6.39	63.2 Millimeters of mercury Standard Deviation 7.21	63.2 Millimeters of mercury Standard Deviation 9.05
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP, Day 1, 24 hours	60.9 Millimeters of mercury Standard Deviation 7.34	63.1 Millimeters of mercury Standard Deviation 8.18	63.0 Millimeters of mercury Standard Deviation 6.40
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP, Day 1, 48 hours	59.8 Millimeters of mercury Standard Deviation 5.89	61.2 Millimeters of mercury Standard Deviation 6.68	59.6 Millimeters of mercury Standard Deviation 4.72
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP, Day 1, 72 hours	58.7 Millimeters of mercury Standard Deviation 6.19	63.0 Millimeters of mercury Standard Deviation 8.69	61.3 Millimeters of mercury Standard Deviation 4.08
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP, Day 5	61.7 Millimeters of mercury Standard Deviation 5.24	64.2 Millimeters of mercury Standard Deviation 6.05	61.5 Millimeters of mercury Standard Deviation 4.18
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) DBP Interval, Day 7	62.0 Millimeters of mercury Standard Deviation 8.46	61.0 Millimeters of mercury Standard Deviation 7.18	59.4 Millimeters of mercury Standard Deviation 5.48
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP, Baseline (Day 1)	108.9 Millimeters of mercury Standard Deviation 11.23	110.6 Millimeters of mercury Standard Deviation 13.47	110.8 Millimeters of mercury Standard Deviation 16.32
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP, Day 1, 24 hours	106.1 Millimeters of mercury Standard Deviation 10.41	112.9 Millimeters of mercury Standard Deviation 13.30	108.7 Millimeters of mercury Standard Deviation 10.54
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP, Day 1, 48 hours	104.7 Millimeters of mercury Standard Deviation 8.60	110.5 Millimeters of mercury Standard Deviation 14.02	106.7 Millimeters of mercury Standard Deviation 10.47
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP, Day 1, 72 hours	100.5 Millimeters of mercury Standard Deviation 6.53	114.7 Millimeters of mercury Standard Deviation 21.57	112.2 Millimeters of mercury Standard Deviation 12.19
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP, Day 5	105.8 Millimeters of mercury Standard Deviation 8.64	118.0 Millimeters of mercury Standard Deviation 19.67	109.2 Millimeters of mercury Standard Deviation 10.98
Part 1: Absolute Values of Vital Sign Parameters: Diastolic Blood Pressure (DBP) and Systolic Blood Pressure (SBP) SBP, Day 7	110.5 Millimeters of mercury Standard Deviation 13.40	108.2 Millimeters of mercury Standard Deviation 9.24	106.8 Millimeters of mercury Standard Deviation 11.94

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Vital Signs: DBP and SBP DBP, Baseline (Day 1 pre-dose)	65.1 Millimeters of mercury Standard Deviation 8.39	65.7 Millimeters of mercury Standard Deviation 9.26	—
Part 2: Absolute Values of Vital Signs: DBP and SBP DBP, Day 1, 24 hours	64.0 Millimeters of mercury Standard Deviation 6.44	62.9 Millimeters of mercury Standard Deviation 9.09	—
Part 2: Absolute Values of Vital Signs: DBP and SBP DBP, Day 1, 48 hours	61.8 Millimeters of mercury Standard Deviation 7.89	61.1 Millimeters of mercury Standard Deviation 9.78	—
Part 2: Absolute Values of Vital Signs: DBP and SBP DBP, Day 5	68.1 Millimeters of mercury Standard Deviation 4.49	60.0 Millimeters of mercury Standard Deviation 4.30	—
Part 2: Absolute Values of Vital Signs: DBP and SBP DBP Interval, Day 7	62.2 Millimeters of mercury Standard Deviation 7.63	67.6 Millimeters of mercury Standard Deviation 7.60	—
Part 2: Absolute Values of Vital Signs: DBP and SBP SBP, Baseline (Day 1 pre-dose)	110.9 Millimeters of mercury Standard Deviation 9.39	111.5 Millimeters of mercury Standard Deviation 11.73	—
Part 2: Absolute Values of Vital Signs: DBP and SBP SBP, Day 1, 24 hours	110.1 Millimeters of mercury Standard Deviation 10.84	110.4 Millimeters of mercury Standard Deviation 13.49	—
Part 2: Absolute Values of Vital Signs: DBP and SBP SBP, Day 1, 48 hours	108.4 Millimeters of mercury Standard Deviation 10.06	106.9 Millimeters of mercury Standard Deviation 9.58	—
Part 2: Absolute Values of Vital Signs: DBP and SBP SBP, Day 5	113.3 Millimeters of mercury Standard Deviation 5.97	108.7 Millimeters of mercury Standard Deviation 9.31	—
Part 2: Absolute Values of Vital Signs: DBP and SBP SBP, Day 7	105.8 Millimeters of mercury Standard Deviation 6.28	108.4 Millimeters of mercury Standard Deviation 9.30	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Vital Signs: Pulse Rate Baseline (Day 1, Pre-dose)	64.9 Beats per minute Standard Deviation 13.41	66.06 Beats per minute Standard Deviation 14.53	67.4 Beats per minute Standard Deviation 14.19
Part 1: Absolute Values of Vital Signs: Pulse Rate Day 1, 24 hours	61.7 Beats per minute Standard Deviation 9.05	68.6 Beats per minute Standard Deviation 11.69	64.8 Beats per minute Standard Deviation 11.47
Part 1: Absolute Values of Vital Signs: Pulse Rate Day 1, 48 hours	61.7 Beats per minute Standard Deviation 6.88	65.5 Beats per minute Standard Deviation 11.81	64.9 Beats per minute Standard Deviation 10.20
Part 1: Absolute Values of Vital Signs: Pulse Rate Day 1, 72 hours	61.2 Beats per minute Standard Deviation 10.76	77.7 Beats per minute Standard Deviation 22.98	57.7 Beats per minute Standard Deviation 10.76
Part 1: Absolute Values of Vital Signs: Pulse Rate Day 5	62.3 Beats per minute Standard Deviation 6.06	77.5 Beats per minute Standard Deviation 20.84	59.7 Beats per minute Standard Deviation 11.81
Part 1: Absolute Values of Vital Signs: Pulse Rate Day 7	58.9 Beats per minute Standard Deviation 8.29	60.8 Beats per minute Standard Deviation 8.49	69.6 Beats per minute Standard Deviation 9.83

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Day 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Vital Signs: Pulse Rate Baseline (Day 1, pre-dose)	64.4 Beats per minute Standard Deviation 5.76	64.2 Beats per minute Standard Deviation 7.34	—
Part 2: Absolute Values of Vital Signs: Pulse Rate Day 1, 24 hours	65.7 Beats per minute Standard Deviation 9.22	67.3 Beats per minute Standard Deviation 8.21	—
Part 2: Absolute Values of Vital Signs: Pulse Rate Day 1, 48 hours	66.9 Beats per minute Standard Deviation 7.29	69.1 Beats per minute Standard Deviation 8.33	—
Part 2: Absolute Values of Vital Signs: Pulse Rate Day 5	70.0 Beats per minute Standard Deviation 7.29	66.8 Beats per minute Standard Deviation 7.10	—
Part 2: Absolute Values of Vital Signs: Pulse Rate Day 7	65.9 Beats per minute Standard Deviation 5.64	62.2 Beats per minute Standard Deviation 7.12	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, 6 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Oral temperature were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Vital Signs: Oral Temperature Baseline (Day 1 pre-dose)	36.38 Degrees celsius Standard Deviation 0.424	36.43 Degrees celsius Standard Deviation 0.451	36.52 Degrees celsius Standard Deviation 0.382
Part 1: Absolute Values of Vital Signs: Oral Temperature Day 1, 24 hours	36.47 Degrees celsius Standard Deviation 0.431	36.55 Degrees celsius Standard Deviation 0.481	36.60 Degrees celsius Standard Deviation 0.422
Part 1: Absolute Values of Vital Signs: Oral Temperature Day 1, 48 hours	36.54 Degrees celsius Standard Deviation 0.343	36.54 Degrees celsius Standard Deviation 0.385	36.61 Degrees celsius Standard Deviation 0.264
Part 1: Absolute Values of Vital Signs: Oral Temperature Day 1, 72 hours	36.45 Degrees celsius Standard Deviation 0.423	36.77 Degrees celsius Standard Deviation 0.314	36.25 Degrees celsius Standard Deviation 0.505
Part 1: Absolute Values of Vital Signs: Oral Temperature Day 5	36.44 Degrees celsius Standard Deviation 0.475	36.43 Degrees celsius Standard Deviation 0.527	36.48 Degrees celsius Standard Deviation 0.355
Part 1: Absolute Values of Vital Signs: Oral Temperature Day 6	36.43 Degrees celsius Standard Deviation 0.317	36.49 Degrees celsius Standard Deviation 0.468	36.43 Degrees celsius Standard Deviation 0.267
Part 1: Absolute Values of Vital Signs: Oral Temperature Day 7	36.51 Degrees celsius Standard Deviation 0.501	36.46 Degrees celsius Standard Deviation 0.380	36.72 Degrees celsius Standard Deviation 0.282

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Day 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Oral temperature were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Vital Signs: Oral Temperature Baseline (Day 1, pre-dose)	36.28 Degree celsius Standard Deviation 0.366	36.30 Degree celsius Standard Deviation 0.230	—
Part 2: Absolute Values of Vital Signs: Oral Temperature Day 1, 24 hours	36.42 Degree celsius Standard Deviation 0.325	36.33 Degree celsius Standard Deviation 0.307	—
Part 2: Absolute Values of Vital Signs: Oral Temperature Day 1, 48 hours	36.42 Degree celsius Standard Deviation 0.321	36.32 Degree celsius Standard Deviation 0.349	—
Part 2: Absolute Values of Vital Signs: Oral Temperature Day 5	36.41 Degree celsius Standard Deviation 0.347	36.31 Degree celsius Standard Deviation 0.313	—
Part 2: Absolute Values of Vital Signs: Oral Temperature Day 6	36.43 Degree celsius Standard Deviation 0.339	36.18 Degree celsius Standard Deviation 0.377	—
Part 2: Absolute Values of Vital Signs: Oral Temperature Day 7	36.57 Degree celsius Standard Deviation 0.269	36.38 Degree celsius Standard Deviation 0.402	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Vital Signs: Respiratory Rate Baseline (Day 1, pre-dose)	14.1 Breaths per minute Standard Deviation 2.65	13.6 Breaths per minute Standard Deviation 2.58	13.9 Breaths per minute Standard Deviation 3.28
Part 1: Absolute Values of Vital Signs: Respiratory Rate Day 1, 24 hours	13.8 Breaths per minute Standard Deviation 3.26	13.8 Breaths per minute Standard Deviation 3.03	14.8 Breaths per minute Standard Deviation 2.93
Part 1: Absolute Values of Vital Signs: Respiratory Rate Day 1, 48 hours	14.9 Breaths per minute Standard Deviation 2.68	12.7 Breaths per minute Standard Deviation 2.42	14.1 Breaths per minute Standard Deviation 2.00
Part 1: Absolute Values of Vital Signs: Respiratory Rate Day 1, 72 hours	14.0 Breaths per minute Standard Deviation 2.83	13.0 Breaths per minute Standard Deviation 2.45	14.0 Breaths per minute Standard Deviation 1.26
Part 1: Absolute Values of Vital Signs: Respiratory Rate Day 5	11.7 Breaths per minute Standard Deviation 3.44	12.0 Breaths per minute Standard Deviation 2.83	14.7 Breaths per minute Standard Deviation 3.93
Part 1: Absolute Values of Vital Signs: Respiratory Rate Day 7	14.0 Breaths per minute Standard Deviation 2.97	14.6 Breaths per minute Standard Deviation 1.89	12.9 Breaths per minute Standard Deviation 3.78

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Vital Signs: Respiratory Rate Baseline (Day 1, pre-dose)	12.7 Breaths per minute Standard Deviation 2.34	12.9 Breaths per minute Standard Deviation 2.49	—
Part 2: Absolute Values of Vital Signs: Respiratory Rate Day 1, 24 hours	14.5 Breaths per minute Standard Deviation 1.94	13.9 Breaths per minute Standard Deviation 2.52	—
Part 2: Absolute Values of Vital Signs: Respiratory Rate Day 1, 48 hours	13.1 Breaths per minute Standard Deviation 2.84	13.8 Breaths per minute Standard Deviation 2.37	—
Part 2: Absolute Values of Vital Signs: Respiratory Rate Day 5	11.3 Breaths per minute Standard Deviation 2.38	12.4 Breaths per minute Standard Deviation 3.13	—
Part 2: Absolute Values of Vital Signs: Respiratory Rate Day 7	13.5 Breaths per minute Standard Deviation 2.07	13.1 Breaths per minute Standard Deviation 1.45	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 1, 24 hours	-0.6 Millimeters of mercury Standard Deviation 5.27	-0.1 Millimeters of mercury Standard Deviation 7.40	13.9 Millimeters of mercury Standard Deviation 7.45
Part 1: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 1, 48 hours	-2.4 Millimeters of mercury Standard Deviation 5.21	-2.5 Millimeters of mercury Standard Deviation 5.25	-2.4 Millimeters of mercury Standard Deviation 5.66
Part 1: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 1, 72 hours	-4.2 Millimeters of mercury Standard Deviation 6.52	-1.3 Millimeters of mercury Standard Deviation 6.86	-1.5 Millimeters of mercury Standard Deviation 6.66
Part 1: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 5	-1.2 Millimeters of mercury Standard Deviation 6.18	-0.2 Millimeters of mercury Standard Deviation 7.25	-1.3 Millimeters of mercury Standard Deviation 5.20
Part 1: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 7	-0.1 Millimeters of mercury Standard Deviation 7.49	-2.3 Millimeters of mercury Standard Deviation 5.76	-2.1 Millimeters of mercury Standard Deviation 8.01
Part 1: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 1, 24 hours	-2.8 Millimeters of mercury Standard Deviation 9.63	2.3 Millimeters of mercury Standard Deviation 7.37	-2.1 Millimeters of mercury Standard Deviation 9.95
Part 1: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 1, 48 hours	-4.0 Millimeters of mercury Standard Deviation 6.08	-0.5 Millimeters of mercury Standard Deviation 6.57	-3.8 Millimeters of mercury Standard Deviation 10.80
Part 1: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 1, 72 hours	-7.8 Millimeters of mercury Standard Deviation 9.09	2.8 Millimeters of mercury Standard Deviation 8.64	4.2 Millimeters of mercury Standard Deviation 6.74
Part 1: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 5	-2.5 Millimeters of mercury Standard Deviation 7.06	6.2 Millimeters of mercury Standard Deviation 9.13	1.2 Millimeters of mercury Standard Deviation 6.52
Part 1: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 7	1.4 Millimeters of mercury Standard Deviation 7.63	-2.4 Millimeters of mercury Standard Deviation 10.06	-5.1 Millimeters of mercury Standard Deviation 10.71

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

SBP and DBP were measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 1, 24 hours	-1.1 Millimeters of mercury Standard Deviation 4.34	-2.8 Millimeters of mercury Standard Deviation 7.18	—
Part 2: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 1, 48 hours	-3.3 Millimeters of mercury Standard Deviation 6.30	-4.6 Millimeters of mercury Standard Deviation 5.28	—
Part 2: Change From Baseline in Vital Signs: DBP and SBP DBP, Day 5	-0.3 Millimeters of mercury Standard Deviation 6.96	-1.8 Millimeters of mercury Standard Deviation 5.54	—
Part 2: Change From Baseline in Vital Signs: DBP and SBP DBP Interval, Day 7	0.1 Millimeters of mercury Standard Deviation 4.48	-2.0 Millimeters of mercury Standard Deviation 6.61	—
Part 2: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 1, 24 hours	-0.8 Millimeters of mercury Standard Deviation 9.19	-1.1 Millimeters of mercury Standard Deviation 10.57	—
Part 2: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 1, 48 hours	-2.5 Millimeters of mercury Standard Deviation 5.56	-4.6 Millimeters of mercury Standard Deviation 7.81	—
Part 2: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 5	1.3 Millimeters of mercury Standard Deviation 10.10	1.9 Millimeters of mercury Standard Deviation 8.22	—
Part 2: Change From Baseline in Vital Signs: DBP and SBP SBP, Day 7	-4.1 Millimeters of mercury Standard Deviation 4.48	-7.8 Millimeters of mercury Standard Deviation 8.74	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Vital Signs: Pulse Rate Day 1, 24 hours	-3.2 Beats per minute Standard Deviation 8.87	2.6 Beats per minute Standard Deviation 8.69	-2.7 Beats per minute Standard Deviation 10.80
Part 1: Change From Baseline in Vital Signs: Pulse Rate Day 1, 48 hours	-0.7 Beats per minute Standard Deviation 9.60	-1.4 Beats per minute Standard Deviation 8.38	-2.8 Beats per minute Standard Deviation 10.94
Part 1: Change From Baseline in Vital Signs: Pulse Rate Day 1, 72 hours	-5.2 Beats per minute Standard Deviation 14.32	7.2 Beats per minute Standard Deviation 5.98	0.7 Beats per minute Standard Deviation 4.41
Part 1: Change From Baseline in Vital Signs: Pulse Rate Day 5	-4.0 Beats per minute Standard Deviation 9.08	7.0 Beats per minute Standard Deviation 6.32	2.7 Beats per minute Standard Deviation 5.89
Part 1: Change From Baseline in Vital Signs: Pulse Rate Day 7	-1.0 Beats per minute Standard Deviation 7.33	-4.4 Beats per minute Standard Deviation 9.63	-4.4 Beats per minute Standard Deviation 9.42

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Pulse rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Vital Signs: Pulse Rate Day 1, 24 hours	1.3 Beats per minute Standard Deviation 9.68	3.1 Beats per minute Standard Deviation 8.32	—
Part 2: Change From Baseline in Vital Signs: Pulse Rate Day 1, 48 hours	2.5 Beats per minute Standard Deviation 5.37	4.9 Beats per minute Standard Deviation 8.36	—
Part 2: Change From Baseline in Vital Signs: Pulse Rate Day 5	7.0 Beats per minute Standard Deviation 8.19	3.4 Beats per minute Standard Deviation 5.32	—
Part 2: Change From Baseline in Vital Signs: Pulse Rate Day 7	0.2 Beats per minute Standard Deviation 4.18	-2.9 Beats per minute Standard Deviation 6.51	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48, 72 hours, Days 5, 6 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Oral temperature was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Vital Signs: Oral Temperature Day 1, 24 hours	0.09 Degrees Celsius Standard Deviation 0.507	0.11 Degrees Celsius Standard Deviation 0.479	0.08 Degrees Celsius Standard Deviation 0.443
Part 1: Change From Baseline in Vital Signs: Oral Temperature Day 1, 48 hours	0.15 Degrees Celsius Standard Deviation 0.485	0.05 Degrees Celsius Standard Deviation 0.415	0.11 Degrees Celsius Standard Deviation 0.274
Part 1: Change From Baseline in Vital Signs: Oral Temperature Day 1, 72 hours	-0.03 Degrees Celsius Standard Deviation 0.497	0.38 Degrees Celsius Standard Deviation 0.313	-0.03 Degrees Celsius Standard Deviation 0.314
Part 1: Change From Baseline in Vital Signs: Oral Temperature Day 5	0.05 Degrees Celsius Standard Deviation 0.418	-0.06 Degrees Celsius Standard Deviation 0.494	-0.03 Degrees Celsius Standard Deviation 0.401
Part 1: Change From Baseline in Vital Signs: Oral Temperature Day 6	0.08 Degrees Celsius Standard Deviation 0.541	-0.04 Degrees Celsius Standard Deviation 0.435	-0.20 Degrees Celsius Standard Deviation 0.521
Part 1: Change From Baseline in Vital Signs: Oral Temperature Day 7	0.17 Degrees Celsius Standard Deviation 0.443	-0.07 Degrees Celsius Standard Deviation 0.523	0.09 Degrees Celsius Standard Deviation 0.300

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, 6 and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Oral temperature was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the latest pre-dose assessment with a non-missing value, including those from unscheduled visits. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Vital Signs: Oral Temperature Day 1, 24 hours	0.14 Degrees Celsius Standard Deviation 0.378	0.03 Degrees Celsius Standard Deviation 0.341	—
Part 2: Change From Baseline in Vital Signs: Oral Temperature Day 1, 48 hours	0.14 Degrees Celsius Standard Deviation 0.326	0.02 Degrees Celsius Standard Deviation 0.350	—
Part 2: Change From Baseline in Vital Signs: Oral Temperature Day 5	0.12 Degrees Celsius Standard Deviation 0.385	0.01 Degrees Celsius Standard Deviation 0.356	—
Part 2: Change From Baseline in Vital Signs: Oral Temperature Day 6	0.11 Degrees Celsius Standard Deviation 0.314	-0.19 Degrees Celsius Standard Deviation 0.481	—
Part 2: Change From Baseline in Vital Signs: Oral Temperature Day 7	0.24 Degrees Celsius Standard Deviation 0.167	0.01 Degrees Celsius Standard Deviation 0.470	—

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Vital Signs: Respiratory Rate Day 1, 24 hours	-0.3 Breaths per minute Standard Deviation 2.57	0.2 Breaths per minute Standard Deviation 3.84	0.9 Breaths per minute Standard Deviation 2.86
Part 1: Change From Baseline in Vital Signs: Respiratory Rate Day 1, 48 hours	0.9 Breaths per minute Standard Deviation 3.64	-0.8 Breaths per minute Standard Deviation 3.67	0.5 Breaths per minute Standard Deviation 2.58
Part 1: Change From Baseline in Vital Signs: Respiratory Rate Day 1, 72 hours	-1.3 Breaths per minute Standard Deviation 2.07	-1.3 Breaths per minute Standard Deviation 3.01	-0.3 Breaths per minute Standard Deviation 2.34
Part 1: Change From Baseline in Vital Signs: Respiratory Rate Day 5	-3.7 Breaths per minute Standard Deviation 2.94	-2.3 Breaths per minute Standard Deviation 4.63	0.3 Breaths per minute Standard Deviation 3.44
Part 1: Change From Baseline in Vital Signs: Respiratory Rate Day 7	0.4 Breaths per minute Standard Deviation 4.37	1.4 Breaths per minute Standard Deviation 2.22	-0.3 Breaths per minute Standard Deviation 3.40

SECONDARY outcome

Timeframe: Baseline (Day 1, pre-dose), and Day 1: 24, 48 hours, Days 5, and 7

Population: Safety Population. Only those participants with data available at the specified time points were analyzed.

Respiratory rate was measured in the semi-supine position with a completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Baseline was defined as the average of the triplicate predose assessments within each treatment. Change from Baseline was calculated by subtracting the Baseline value from the post-dose visit value.

Outcome measures

Outcome measures
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Vital Signs: Respiratory Rate Day 1, 24 hours	1.8 Breaths per minute Standard Deviation 2.82	1.0 Breaths per minute Standard Deviation 3.01	—
Part 2: Change From Baseline in Vital Signs: Respiratory Rate Day 1, 48 hours	0.4 Breaths per minute Standard Deviation 3.48	0.9 Breaths per minute Standard Deviation 3.01	—
Part 2: Change From Baseline in Vital Signs: Respiratory Rate Day 5	-1.0 Breaths per minute Standard Deviation 3.02	-1.3 Breaths per minute Standard Deviation 4.24	—
Part 2: Change From Baseline in Vital Signs: Respiratory Rate Day 7	0.0 Breaths per minute Standard Deviation 2.83	1.1 Breaths per minute Standard Deviation 3.33	—

Adverse Events

Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet)

Serious events: 0 serious events

Other events: 0 other events

Deaths: 0 deaths

Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet)

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed)

Serious events: 0 serious events

Other events: 1 other events

Deaths: 0 deaths

Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted)

Serious events: 0 serious events

Other events: 2 other events

Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 participants at risk Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 participants at risk Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 participants at risk Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 2: Treatment D: GSK3640254/DTG, 150 mg/50 mg (Fed) n=17 participants at risk Participants received Treatment D a single oral dose of selected bilayer FDC from Part 1 of GSK3640254/DTG, 150 mg/50 mg under high fat and calorie conditions on Day 1 in each treatment period.	Part 2: Treatment E: GSK3640254/DTG, 150 mg/50 mg (Fasted) n=18 participants at risk Participants received Treatment E a single oral dose of selected bilayer FDC from Part 1 GSK3640254/DTG, 150 mg/50 mg administered under fasted conditions on Day 1 in each treatment period.
Psychiatric disorders Anxiety	0.00% 0/22 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/21 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	5.0% 1/20 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/17 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/18 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.
General disorders Fatigue	0.00% 0/22 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/21 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/20 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	5.9% 1/17 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/18 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.
Investigations SARS-CoV-2 test positive	0.00% 0/22 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/21 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/20 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/17 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	5.6% 1/18 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.
Musculoskeletal and connective tissue disorders Back pain	0.00% 0/22 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/21 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/20 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/17 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	5.6% 1/18 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.
Nervous system disorders Dizziness	0.00% 0/22 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/21 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/20 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	5.9% 1/17 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.	0.00% 0/18 • All-cause mortality, non-serious adverse events (Non-SAEs) and serious adverse events (SAEs) were collected up to Day 17 in Part 1 and up to Day 9 in Part 2 Safety Population consisted of all participants who received at least one dose of study intervention.

Additional Information

GSK Response Center

ViiV Healthcare

Phone: 866-435-7343

Email: [email protected]

Results disclosure agreements

Principal investigator is a sponsor employee GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.
Publication restrictions are in place

Restriction type: OTHER

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 2	1.647 10^9 cells per liter Standard Deviation 0.3715	1.735 10^9 cells per liter Standard Deviation 0.3019	1.711 10^9 cells per liter Standard Deviation 0.3950
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 5	1.835 10^9 cells per liter Standard Deviation 0.4113	1.663 10^9 cells per liter Standard Deviation 0.4034	1.705 10^9 cells per liter Standard Deviation 0.4574
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 7	1.630 10^9 cells per liter Standard Deviation 0.3049	1.675 10^9 cells per liter Standard Deviation 0.3398	1.592 10^9 cells per liter Standard Deviation 0.3674
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Baseline (Day -1)	0.396 10^9 cells per liter Standard Deviation 0.0834	0.396 10^9 cells per liter Standard Deviation 0.0878	0.419 10^9 cells per liter Standard Deviation 0.1464
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 2	0.395 10^9 cells per liter Standard Deviation 0.0803	0.389 10^9 cells per liter Standard Deviation 0.0861	0.410 10^9 cells per liter Standard Deviation 0.0932
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 5	0.422 10^9 cells per liter Standard Deviation 0.0987	0.387 10^9 cells per liter Standard Deviation 0.0497	0.380 10^9 cells per liter Standard Deviation 0.1243
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 7	0.380 10^9 cells per liter Standard Deviation 0.0587	0.398 10^9 cells per liter Standard Deviation 0.1162	0.410 10^9 cells per liter Standard Deviation 0.0903
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Baseline (Day -1)	2.729 10^9 cells per liter Standard Deviation 0.8510	2.691 10^9 cells per liter Standard Deviation 1.0455	2.906 10^9 cells per liter Standard Deviation 1.3028
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 2	2.756 10^9 cells per liter Standard Deviation 0.8228	2.589 10^9 cells per liter Standard Deviation 0.9598	2.573 10^9 cells per liter Standard Deviation 0.9203
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 5	2.967 10^9 cells per liter Standard Deviation 0.8932	2.648 10^9 cells per liter Standard Deviation 0.8738	2.703 10^9 cells per liter Standard Deviation 2.0389
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 7	2.462 10^9 cells per liter Standard Deviation 0.9607	2.594 10^9 cells per liter Standard Deviation 1.1921	2.812 10^9 cells per liter Standard Deviation 0.9202
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Baseline (Day -1)	247.8 10^9 cells per liter Standard Deviation 45.94	252.5 10^9 cells per liter Standard Deviation 52.73	256.5 10^9 cells per liter Standard Deviation 50.02
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 2	254.6 10^9 cells per liter Standard Deviation 46.26	257.0 10^9 cells per liter Standard Deviation 54.66	260.4 10^9 cells per liter Standard Deviation 52.24
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 5	277.8 10^9 cells per liter Standard Deviation 35.13	268.7 10^9 cells per liter Standard Deviation 52.38	212.2 10^9 cells per liter Standard Deviation 44.62
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 7	237.9 10^9 cells per liter Standard Deviation 40.40	257.1 10^9 cells per liter Standard Deviation 55.49	271.4 10^9 cells per liter Standard Deviation 44.96
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Baseline (Day -1)	0.035 10^9 cells per liter Standard Deviation 0.0144	0.036 10^9 cells per liter Standard Deviation 0.0140	0.036 10^9 cells per liter Standard Deviation 0.0132
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 2	0.036 10^9 cells per liter Standard Deviation 0.0133	0.036 10^9 cells per liter Standard Deviation 0.0120	0.037 10^9 cells per liter Standard Deviation 0.0184
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 5	0.045 10^9 cells per liter Standard Deviation 0.0138	0.035 10^9 cells per liter Standard Deviation 0.0187	0.028 10^9 cells per liter Standard Deviation 0.0117
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 7	0.033 10^9 cells per liter Standard Deviation 0.0142	0.040 10^9 cells per liter Standard Deviation 0.0108	0.038 10^9 cells per liter Standard Deviation 0.0169
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Baseline (Day -1)	0.157 10^9 cells per liter Standard Deviation 0.1455	0.150 10^9 cells per liter Standard Deviation 0.1300	0.171 10^9 cells per liter Standard Deviation 0.1559
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 2	0.157 10^9 cells per liter Standard Deviation 0.1382	0.146 10^9 cells per liter Standard Deviation 0.1229	0.170 10^9 cells per liter Standard Deviation 0.1482
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 5	0.197 10^9 cells per liter Standard Deviation 0.1481	0.182 10^9 cells per liter Standard Deviation 0.1512	0.120 10^9 cells per liter Standard Deviation 0.1210
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 7	0.141 10^9 cells per liter Standard Deviation 0.1272	0.152 10^9 cells per liter Standard Deviation 0.1194	0.189 10^9 cells per liter Standard Deviation 0.1613
Part 1: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Baseline (Day -1)	1.683 10^9 cells per liter Standard Deviation 0.3691	1.674 10^9 cells per liter Standard Deviation 0.2885	1.646 10^9 cells per liter Standard Deviation 0.3375

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Baseline (Day -1)	0.046 10^9 cells per liter Standard Deviation 0.0289	0.041 10^9 cells per liter Standard Deviation 0.0242	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 2	0.038 10^9 cells per liter Standard Deviation 0.0183	0.041 10^9 cells per liter Standard Deviation 0.0192	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 5	0.051 10^9 cells per liter Standard Deviation 0.0253	0.037 10^9 cells per liter Standard Deviation 0.0141	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 7	0.033 10^9 cells per liter Standard Deviation 0.0141	0.057 10^9 cells per liter Standard Deviation 0.0354	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Baseline (Day -1)	0.128 10^9 cells per liter Standard Deviation 0.0688	0.138 10^9 cells per liter Standard Deviation 0.0880	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 2	0.125 10^9 cells per liter Standard Deviation 0.0700	0.136 10^9 cells per liter Standard Deviation 0.0786	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 5	0.131 10^9 cells per liter Standard Deviation 0.0869	0.111 10^9 cells per liter Standard Deviation 0.0601	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 7	0.123 10^9 cells per liter Standard Deviation 0.0726	0.133 10^9 cells per liter Standard Deviation 0.0652	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Baseline (Day -1)	1.786 10^9 cells per liter Standard Deviation 0.4445	1.771 10^9 cells per liter Standard Deviation 0.4902	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 2	1.884 10^9 cells per liter Standard Deviation 0.4805	1.838 10^9 cells per liter Standard Deviation 0.4761	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 5	1.663 10^9 cells per liter Standard Deviation 0.5135	1.750 10^9 cells per liter Standard Deviation 0.3384	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 7	1.827 10^9 cells per liter Standard Deviation 0.3937	1.730 10^9 cells per liter Standard Deviation 0.5080	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Baseline (Day -1)	0.466 10^9 cells per liter Standard Deviation 0.1086	0.443 10^9 cells per liter Standard Deviation 0.1100	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 2	0.452 10^9 cells per liter Standard Deviation 0.1114	0.458 10^9 cells per liter Standard Deviation 0.1070	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 5	0.479 10^9 cells per liter Standard Deviation 0.1512	0.430 10^9 cells per liter Standard Deviation 0.1021	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 7	0.452 10^9 cells per liter Standard Deviation 0.0987	0.469 10^9 cells per liter Standard Deviation 0.1102	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Baseline (Day -1)	3.094 10^9 cells per liter Standard Deviation 1.1911	3.138 10^9 cells per liter Standard Deviation 1.1817	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 2	2.999 10^9 cells per liter Standard Deviation 1.1184	3.122 10^9 cells per liter Standard Deviation 1.1220	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 5	3.891 10^9 cells per liter Standard Deviation 2.1672	3.234 10^9 cells per liter Standard Deviation 1.3698	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 7	2.967 10^9 cells per liter Standard Deviation 1.0973	3.083 10^9 cells per liter Standard Deviation 1.1599	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Baseline (Day -1)	291.6 10^9 cells per liter Standard Deviation 53.57	292.7 10^9 cells per liter Standard Deviation 59.84	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 2	302.0 10^9 cells per liter Standard Deviation 56.30	299.7 10^9 cells per liter Standard Deviation 62.53	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 5	278.6 10^9 cells per liter Standard Deviation 61.63	314.1 10^9 cells per liter Standard Deviation 53.97	—
Part 2: Absolute Values for Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 7	307.4 10^9 cells per liter Standard Deviation 55.38	274.4 10^9 cells per liter Standard Deviation 61.27	—

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=21 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 2	0.000 10^9 cells per liter Standard Deviation 0.0112	0.000 10^9 cells per liter Standard Deviation 0.0128	0.002 10^9 cells per liter Standard Deviation 0.0114
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 5	0.003 10^9 cells per liter Standard Deviation 0.0137	0.002 10^9 cells per liter Standard Deviation 0.0117	-0.007 10^9 cells per liter Standard Deviation 0.0121
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Basophils, Day 7	0.002 10^9 cells per liter Standard Deviation 0.0075	0.002 10^9 cells per liter Standard Deviation 0.0109	0.006 10^9 cells per liter Standard Deviation 0.0117
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 2	-0.005 10^9 cells per liter Standard Deviation 0.0340	-0.004 10^9 cells per liter Standard Deviation 0.0393	-0.001 10^9 cells per liter Standard Deviation 0.0253
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 5	0.012 10^9 cells per liter Standard Deviation 0.0722	-0.020 10^9 cells per liter Standard Deviation 0.0379	-0.022 10^9 cells per liter Standard Deviation 0.0739
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Eosinophils, Day 7	0.006 10^9 cells per liter Standard Deviation 0.0437	0.013 10^9 cells per liter Standard Deviation 0.0632	-0.015 10^9 cells per liter Standard Deviation 0.0450
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 2	-0.006 10^9 cells per liter Standard Deviation 0.2568	0.061 10^9 cells per liter Standard Deviation 0.1626	0.065 10^9 cells per liter Standard Deviation 0.1831
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 5	0.012 10^9 cells per liter Standard Deviation 0.2670	-0.103 10^9 cells per liter Standard Deviation 0.2293	0.053 10^9 cells per liter Standard Deviation 0.5253
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Lymphocytes, Day 7	-0.023 10^9 cells per liter Standard Deviation 0.1443	0.069 10^9 cells per liter Standard Deviation 0.2843	0.031 10^9 cells per liter Standard Deviation 0.2409
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 2	0.000 10^9 cells per liter Standard Deviation 0.0662	-0.008 10^9 cells per liter Standard Deviation 0.0650	-0.009 10^9 cells per liter Standard Deviation 0.1268
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 5	-0.022 10^9 cells per liter Standard Deviation 0.0679	0.000 10^9 cells per liter Standard Deviation 0.0672	0.012 10^9 cells per liter Standard Deviation 0.0286
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Monocytes, Day 7	-0.006 10^9 cells per liter Standard Deviation 0.0585	-0.005 10^9 cells per liter Standard Deviation 0.0901	-0.044 10^9 cells per liter Standard Deviation 0.1607
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 2	0.000 10^9 cells per liter Standard Deviation 0.6401	-0.103 10^9 cells per liter Standard Deviation 0.6015	-0.334 10^9 cells per liter Standard Deviation 0.9923
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 5	0.092 10^9 cells per liter Standard Deviation 0.4511	0.007 10^9 cells per liter Standard Deviation 0.1939	0.222 10^9 cells per liter Standard Deviation 1.1719
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Neutrophils, Day 7	-0.269 10^9 cells per liter Standard Deviation 0.6770	-0.066 10^9 cells per liter Standard Deviation 0.6836	-0.642 10^9 cells per liter Standard Deviation 1.3252
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 2	4.4 10^9 cells per liter Standard Deviation 9.28	4.5 10^9 cells per liter Standard Deviation 15.78	4.0 10^9 cells per liter Standard Deviation 14.96
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 5	5.2 10^9 cells per liter Standard Deviation 13.27	-1.5 10^9 cells per liter Standard Deviation 15.06	-7.5 10^9 cells per liter Standard Deviation 16.21
Part 1: Change From Baseline in Hematology Parameters: Basophils, Eosinophils, Lymphocytes, Monocytes, Neutrophils, Platelets Platelets, Day 7	-2.2 10^9 cells per liter Standard Deviation 20.03	7.9 10^9 cells per liter Standard Deviation 26.01	3.1 10^9 cells per liter Standard Deviation 32.56

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALT, Baseline (Day -1)	16.4 International units per Liter Standard Deviation 9.44	19.1 International units per Liter Standard Deviation 13.65	18.9 International units per Liter Standard Deviation 15.33
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALT, Day 2	16.3 International units per Liter Standard Deviation 9.32	17.4 International units per Liter Standard Deviation 9.99	18.4 International units per Liter Standard Deviation 12.29
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALT, Day 5	14.0 International units per Liter Standard Deviation 4.56	16.7 International units per Liter Standard Deviation 8.64	19.5 International units per Liter Standard Deviation 16.67
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALT, Day 7	20.5 International units per Liter Standard Deviation 14.81	20.8 International units per Liter Standard Deviation 18.34	17.2 International units per Liter Standard Deviation 9.60
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALP, Baseline (Day -1)	54.6 International units per Liter Standard Deviation 14.90	55.6 International units per Liter Standard Deviation 15.14	53.4 International units per Liter Standard Deviation 15.34
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALP, Day 2	56.5 International units per Liter Standard Deviation 14.72	57.6 International units per Liter Standard Deviation 14.03	55.2 International units per Liter Standard Deviation 15.58
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALP, Day 5	49.8 International units per Liter Standard Deviation 13.69	60.8 International units per Liter Standard Deviation 12.62	53.8 International units per Liter Standard Deviation 17.62
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) ALP, Day 7	55.1 International units per Liter Standard Deviation 14.74	52.8 International units per Liter Standard Deviation 16.34	59.3 International units per Liter Standard Deviation 16.35
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) AST, Baseline (Day -1)	16.3 International units per Liter Standard Deviation 4.84	17.0 International units per Liter Standard Deviation 5.63	17.1 International units per Liter Standard Deviation 6.23
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) AST, Day 2	15.8 International units per Liter Standard Deviation 4.02	16.1 International units per Liter Standard Deviation 4.57	17.1 International units per Liter Standard Deviation 5.92
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) AST, Day 5	14.8 International units per Liter Standard Deviation 4.26	16.2 International units per Liter Standard Deviation 4.92	16.3 International units per Liter Standard Deviation 2.07
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) AST, Day 7	16.5 International units per Liter Standard Deviation 5.13	17.5 International units per Liter Standard Deviation 7.31	17.5 International units per Liter Standard Deviation 6.19
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) GGT, Baseline (Day -1)	22.1 International units per Liter Standard Deviation 15.68	22.9 International units per Liter Standard Deviation 16.21	22.2 International units per Liter Standard Deviation 15.53
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) GGT, Day 2	22.0 International units per Liter Standard Deviation 14.57	22.8 International units per Liter Standard Deviation 15.45	22.7 International units per Liter Standard Deviation 13.77
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) GGT, Day 5	22.3 International units per Liter Standard Deviation 19.38	21.8 International units per Liter Standard Deviation 6.11	20.5 International units per Liter Standard Deviation 12.36
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) GGT, Day 7	21.4 International units per Liter Standard Deviation 10.08	22.9 International units per Liter Standard Deviation 18.60	26.8 International units per Liter Standard Deviation 20.97
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) LDH, Baseline (Day -1)	121.7 International units per Liter Standard Deviation 19.59	121.0 International units per Liter Standard Deviation 24.41	119.5 International units per Liter Standard Deviation 22.30
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) LDH, Day 2	119.1 International units per Liter Standard Deviation 16.92	120.1 International units per Liter Standard Deviation 23.02	123.5 International units per Liter Standard Deviation 25.15
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) LDH, Day 5	119.5 International units per Liter Standard Deviation 15.54	114.0 International units per Liter Standard Deviation 21.22	107.5 International units per Liter Standard Deviation 16.08
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) LDH, Day 7	105.3 International units per Liter Standard Deviation 12.41	118.1 International units per Liter Standard Deviation 22.72	116.0 International units per Liter Standard Deviation 20.23
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) CK, Baseline (Day -1)	101.0 International units per Liter Standard Deviation 49.01	115.1 International units per Liter Standard Deviation 114.93	106.8 International units per Liter Standard Deviation 93.82
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) CK, Day 2	89.7 International units per Liter Standard Deviation 51.73	104.8 International units per Liter Standard Deviation 109.70	107.0 International units per Liter Standard Deviation 114.66
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) CK, Day 5	69.0 International units per Liter Standard Deviation 33.00	96.5 International units per Liter Standard Deviation 63.32	85.8 International units per Liter Standard Deviation 40.74
Part 1: Absolute Values for Clinical Chemistry Parameters: Alanine Amino Transferase (ALT), Alkaline Phosphatase (ALP), Aspartate Amino Transferase (AST), Gamma Glutamyl Transferase (GGT), Lactate Dehydrogenase (LDH), Creatinine Kinase (CK) CK, Day 7	90.8 International units per Liter Standard Deviation 51.77	104.6 International units per Liter Standard Deviation 109.85	88.2 International units per Liter Standard Deviation 46.19

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Baseline (Day -1)	18.9 International units per Liter Standard Deviation 12.42	18.8 International units per Liter Standard Deviation 13.37	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 2	18.6 International units per Liter Standard Deviation 11.57	18.9 International units per Liter Standard Deviation 12.65	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 5	18.5 International units per Liter Standard Deviation 11.82	25.2 International units per Liter Standard Deviation 20.47	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 7	21.8 International units per Liter Standard Deviation 16.34	18.1 International units per Liter Standard Deviation 9.97	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP Baseline (Day -1)	63.2 International units per Liter Standard Deviation 18.86	61.6 International units per Liter Standard Deviation 18.57	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 2	62.1 International units per Liter Standard Deviation 18.43	62.1 International units per Liter Standard Deviation 18.75	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 5	61.6 International units per Liter Standard Deviation 18.18	70.4 International units per Liter Standard Deviation 21.18	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 7	66.6 International units per Liter Standard Deviation 17.59	58.8 International units per Liter Standard Deviation 19.73	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Baseline (Day -1)	16.4 International units per Liter Standard Deviation 4.15	16.7 International units per Liter Standard Deviation 4.92	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 2	15.6 International units per Liter Standard Deviation 3.36	16.1 International units per Liter Standard Deviation 4.30	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 5	17.0 International units per Liter Standard Deviation 2.88	20.1 International units per Liter Standard Deviation 7.79	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 7	17.7 International units per Liter Standard Deviation 6.56	15.9 International units per Liter Standard Deviation 2.71	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Baseline (Day -1)	21.6 International units per Liter Standard Deviation 8.81	21.7 International units per Liter Standard Deviation 9.34	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 2	20.9 International units per Liter Standard Deviation 8.62	22.2 International units per Liter Standard Deviation 9.67	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 5	21.6 International units per Liter Standard Deviation 8.33	22.8 International units per Liter Standard Deviation 11.91	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 7	20.8 International units per Liter Standard Deviation 9.65	21.8 International units per Liter Standard Deviation 8.30	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Baseline (Day -1)	125.5 International units per Liter Standard Deviation 14.23	123.4 International units per Liter Standard Deviation 14.62	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 2	117.8 International units per Liter Standard Deviation 13.32	118.4 International units per Liter Standard Deviation 11.64	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 5	122.6 International units per Liter Standard Deviation 16.59	122.6 International units per Liter Standard Deviation 14.56	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 7	119.2 International units per Liter Standard Deviation 14.92	124.9 International units per Liter Standard Deviation 17.95	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Baseline (Day -1)	101.8 International units per Liter Standard Deviation 52.32	103.3 International units per Liter Standard Deviation 56.84	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 2	89.5 International units per Liter Standard Deviation 45.43	89.9 International units per Liter Standard Deviation 41.11	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 5	95.8 International units per Liter Standard Deviation 38.31	99.8 International units per Liter Standard Deviation 65.97	—
Part 2: Absolute Values of Clinical Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 7	97.7 International units per Liter Standard Deviation 65.84	85.9 International units per Liter Standard Deviation 31.47	—

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Baseline (Day -1)	2.357 Millimoles per liter Standard Deviation 0.0999	2.366 Millimoles per liter Standard Deviation 0.1034	2.347 Millimoles per liter Standard Deviation 0.0839
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 2	2.371 Millimoles per liter Standard Deviation 0.0986	2.377 Millimoles per liter Standard Deviation 0.0868	2.379 Millimoles per liter Standard Deviation 0.1009
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 5	2.345 Millimoles per liter Standard Deviation 0.0948	2.407 Millimoles per liter Standard Deviation 0.0509	2.393 Millimoles per liter Standard Deviation 0.1171
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 7	2.380 Millimoles per liter Standard Deviation 0.0949	2.348 Millimoles per liter Standard Deviation 0.1014	2.371 Millimoles per liter Standard Deviation 0.1201
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Baseline (Day -1)	30.5 Millimoles per liter Standard Deviation 1.90	30.2 Millimoles per liter Standard Deviation 2.14	30.3 Millimoles per liter Standard Deviation 1.83
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 2	29.4 Millimoles per liter Standard Deviation 2.24	29.8 Millimoles per liter Standard Deviation 2.12	29.8 Millimoles per liter Standard Deviation 2.36
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 5	28.2 Millimoles per liter Standard Deviation 1.94	29.3 Millimoles per liter Standard Deviation 2.34	29.7 Millimoles per liter Standard Deviation 2.50
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 7	30.5 Millimoles per liter Standard Deviation 2.50	30.5 Millimoles per liter Standard Deviation 1.98	30.0 Millimoles per liter Standard Deviation 2.05
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Baseline (Day -1)	101.7 Millimoles per liter Standard Deviation 1.49	101.8 Millimoles per liter Standard Deviation 2.07	102.1 Millimoles per liter Standard Deviation 2.21
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 2	102.0 Millimoles per liter Standard Deviation 2.53	101.6 Millimoles per liter Standard Deviation 2.11	102.0 Millimoles per liter Standard Deviation 2.32
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 5	102.8 Millimoles per liter Standard Deviation 1.47	101.3 Millimoles per liter Standard Deviation 2.16	101.7 Millimoles per liter Standard Deviation 1.86
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 7	101.9 Millimoles per liter Standard Deviation 1.92	102.4 Millimoles per liter Standard Deviation 2.02	101.8 Millimoles per liter Standard Deviation 1.03
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Baseline (Day -1)	5.125 Millimoles per liter Standard Deviation 0.4472	5.114 Millimoles per liter Standard Deviation 0.3745	5.074 Millimoles per liter Standard Deviation 0.3816
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 2	4.927 Millimoles per liter Standard Deviation 0.4659	4.979 Millimoles per liter Standard Deviation 0.4960	4.813 Millimoles per liter Standard Deviation 0.4044
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 5	4.643 Millimoles per liter Standard Deviation 0.3725	5.153 Millimoles per liter Standard Deviation 0.3527	5.123 Millimoles per liter Standard Deviation 0.4912
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 7	5.207 Millimoles per liter Standard Deviation 0.3982	4.980 Millimoles per liter Standard Deviation 0.4112	4.946 Millimoles per liter Standard Deviation 0.3303
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Baseline (Day -1)	4.20 Millimoles per liter Standard Deviation 0.233	4.30 Millimoles per liter Standard Deviation 4.24	4.24 Millimoles per liter Standard Deviation 0.315
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 2	4.22 Millimoles per liter Standard Deviation 0.246	4.12 Millimoles per liter Standard Deviation 0.266	4.27 Millimoles per liter Standard Deviation 0.334
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 5	4.18 Millimoles per liter Standard Deviation 0.147	4.08 Millimoles per liter Standard Deviation 0.271	4.15 Millimoles per liter Standard Deviation 0.513
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 7	4.35 Millimoles per liter Standard Deviation 0.383	4.24 Millimoles per liter Standard Deviation 0.331	4.16 Millimoles per liter Standard Deviation 0.165
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Baseline (Day -1)	137.5 Millimoles per liter Standard Deviation 2.48	137.9 Millimoles per liter Standard Deviation 2.15	137.6 Millimoles per liter Standard Deviation 2.37
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 2	137.5 Millimoles per liter Standard Deviation 2.22	137.8 Millimoles per liter Standard Deviation 1.73	137.9 Millimoles per liter Standard Deviation 1.76
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 5	137.8 Millimoles per liter Standard Deviation 1.83	137.2 Millimoles per liter Standard Deviation 2.14	137.8 Millimoles per liter Standard Deviation 2.64
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 7	138.2 Millimoles per liter Standard Deviation 1.99	138.2 Millimoles per liter Standard Deviation 2.20	137.2 Millimoles per liter Standard Deviation 2.39
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Baseline (Day -1)	4.105 Millimoles per liter Standard Deviation 0.9931	4.398 Millimoles per liter Standard Deviation 0.9260	4.216 Millimoles per liter Standard Deviation 0.5976
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 2	4.625 Millimoles per liter Standard Deviation 0.8713	4.731 Millimoles per liter Standard Deviation 0.8265	4.491 Millimoles per liter Standard Deviation 0.8115
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 5	3.980 Millimoles per liter Standard Deviation 0.4246	4.378 Millimoles per liter Standard Deviation 0.6674	4.368 Millimoles per liter Standard Deviation 0.6707
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 7	4.810 Millimoles per liter Standard Deviation 1.0170	4.220 Millimoles per liter Standard Deviation 0.5511	4.439 Millimoles per liter Standard Deviation 1.0769
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Baseline (Day -1)	1.126 Millimoles per liter Standard Deviation 0.1429	1.095 Millimoles per liter Standard Deviation 0.1602	1.156 Millimoles per liter Standard Deviation 0.1414
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 2	1.195 Millimoles per liter Standard Deviation 0.1672	1.173 Millimoles per liter Standard Deviation 0.1474	1.238 Millimoles per liter Standard Deviation 0.1306
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 5	1.267 Millimoles per liter Standard Deviation 0.1007	1.142 Millimoles per liter Standard Deviation 0.2344	1.178 Millimoles per liter Standard Deviation 0.1574
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 7	1.114 Millimoles per liter Standard Deviation 0.0886	1.198 Millimoles per liter Standard Deviation 0.1058	1.172 Millimoles per liter Standard Deviation 0.1494
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Baseline (Day -1)	1.161 Millimoles per liter Standard Deviation 0.3495	1.284 Millimoles per liter Standard Deviation 0.6031	1.011 Millimoles per liter Standard Deviation 0.3381
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 2	1.255 Millimoles per liter Standard Deviation 0.5400	1.271 Millimoles per liter Standard Deviation 0.6676	1.022 Millimoles per liter Standard Deviation 0.3455
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 5	0.907 Millimoles per liter Standard Deviation 0.2482	1.020 Millimoles per liter Standard Deviation 0.4494	0.827 Millimoles per liter Standard Deviation 0.2523
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides Day 7	1.316 Millimoles per liter Standard Deviation 0.6488	0.972 Millimoles per liter Standard Deviation 0.3031	1.048 Millimoles per liter Standard Deviation 0.3121
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Baseline (Day -1)	4.666 Millimoles per liter Standard Deviation 0.6505	4.737 Millimoles per liter Standard Deviation 0.7591	4.674 Millimoles per liter Standard Deviation 0.6908
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 2	4.783 Millimoles per liter Standard Deviation 0.6972	4.795 Millimoles per liter Standard Deviation 0.7617	4.726 Millimoles per liter Standard Deviation 0.7404
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 5	4.863 Millimoles per liter Standard Deviation 0.6029	4.507 Millimoles per liter Standard Deviation 1.2255	4.292 Millimoles per liter Standard Deviation 0.4032
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 7	4.415 Millimoles per liter Standard Deviation 0.5871	4.776 Millimoles per liter Standard Deviation 0.6017	4.590 Millimoles per liter Standard Deviation 0.7417
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Baseline (Day -1)	9.5 Millimoles per liter Standard Deviation 1.30	10.1 Millimoles per liter Standard Deviation 1.62	9.6 Millimoles per liter Standard Deviation 1.43
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 2	10.3 Millimoles per liter Standard Deviation 1.94	10.5 Millimoles per liter Standard Deviation 1.29	10.3 Millimoles per liter Standard Deviation 2.23
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 5	10.8 Millimoles per liter Standard Deviation 1.72	10.7 Millimoles per liter Standard Deviation 1.63	10.8 Millimoles per liter Standard Deviation 1.72
Part 1: Absolute Values of Clinical Chemistry Parameters: Calcium, Carbon-dioxide (CO2), Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 7	10.2 Millimoles per liter Standard Deviation 1.25	9.7 Millimoles per liter Standard Deviation 1.38	9.4 Millimoles per liter Standard Deviation 1.65

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Baseline (Day -1)	2.356 Millimoles per liter Standard Deviation 0.0947	2.354 Millimoles per liter Standard Deviation 0.0833	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 2	2.343 Millimoles per liter Standard Deviation 0.0922	2.362 Millimoles per liter Standard Deviation 0.0854	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 5	2.315 Millimoles per liter Standard Deviation 0.0991	2.381 Millimoles per liter Standard Deviation 0.0764	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 7	2.362 Millimoles per liter Standard Deviation 0.1049	2.340 Millimoles per liter Standard Deviation 0.0616	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Baseline (Day -1)	31.2 Millimoles per liter Standard Deviation 1.42	31.1 Millimoles per liter Standard Deviation 1.51	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 2	29.8 Millimoles per liter Standard Deviation 2.10	30.1 Millimoles per liter Standard Deviation 2.10	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 5	30.1 Millimoles per liter Standard Deviation 1.64	30.8 Millimoles per liter Standard Deviation 1.86	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 7	31.3 Millimoles per liter Standard Deviation 1.87	31.1 Millimoles per liter Standard Deviation 1.17	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Baseline (Day -1)	101.8 Millimoles per liter Standard Deviation 2.11	102.1 Millimoles per liter Standard Deviation 1.45	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 2	102.3 Millimoles per liter Standard Deviation 1.34	101.7 Millimoles per liter Standard Deviation 1.64	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 5	102.0 Millimoles per liter Standard Deviation 1.93	101.4 Millimoles per liter Standard Deviation 1.01	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 7	102.3 Millimoles per liter Standard Deviation 1.87	102.1 Millimoles per liter Standard Deviation 2.20	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Baseline (Day -1)	4.872 Millimoles per liter Standard Deviation 0.3107	4.913 Millimoles per liter Standard Deviation 0.3252	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 2	4.784 Millimoles per liter Standard Deviation 0.3470	4.989 Millimoles per liter Standard Deviation 0.3379	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 5	4.606 Millimoles per liter Standard Deviation 0.3351	4.729 Millimoles per liter Standard Deviation 0.1985	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 7	4.984 Millimoles per liter Standard Deviation 0.3691	4.754 Millimoles per liter Standard Deviation 0.3304	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Baseline (Day -1)	4.29 Millimoles per liter Standard Deviation 0.183	4.27 Millimoles per liter Standard Deviation 0.225	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 2	4.30 Millimoles per liter Standard Deviation 0.193	4.36 Millimoles per liter Standard Deviation 0.350	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 5	4.33 Millimoles per liter Standard Deviation 0.369	4.18 Millimoles per liter Standard Deviation 0.222	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 7	4.26 Millimoles per liter Standard Deviation 0.133	4.46 Millimoles per liter Standard Deviation 0.364	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Baseline (Day -1)	138.2 Millimoles per liter Standard Deviation 2.02	138.1 Millimoles per liter Standard Deviation 1.55	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 2	137.8 Millimoles per liter Standard Deviation 1.83	137.8 Millimoles per liter Standard Deviation 2.39	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 5	137.4 Millimoles per liter Standard Deviation 1.69	138.1 Millimoles per liter Standard Deviation 1.90	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 7	138.9 Millimoles per liter Standard Deviation 1.17	138.4 Millimoles per liter Standard Deviation 2.40	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Baseline (Day -1)	4.193 Millimoles per liter Standard Deviation 0.9707	4.289 Millimoles per liter Standard Deviation 0.8517	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 2	4.511 Millimoles per liter Standard Deviation 0.8025	4.917 Millimoles per liter Standard Deviation 1.2215	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 5	4.488 Millimoles per liter Standard Deviation 0.7840	4.197 Millimoles per liter Standard Deviation 0.9577	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 7	4.130 Millimoles per liter Standard Deviation 0.9850	4.889 Millimoles per liter Standard Deviation 1.2618	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Baseline (Day -1)	1.129 Millimoles per liter Standard Deviation 0.1711	1.137 Millimoles per liter Standard Deviation 0.1644	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 2	1.163 Millimoles per liter Standard Deviation 0.1414	1.181 Millimoles per liter Standard Deviation 0.1402	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 5	1.149 Millimoles per liter Standard Deviation 0.1183	1.159 Millimoles per liter Standard Deviation 0.1837	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 7	1.147 Millimoles per liter Standard Deviation 0.1777	1.146 Millimoles per liter Standard Deviation 0.1261	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Baseline (Day -1)	1.380 Millimoles per liter Standard Deviation 0.5675	1.346 Millimoles per liter Standard Deviation 0.6796	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 2	1.255 Millimoles per liter Standard Deviation 0.5644	1.226 Millimoles per liter Standard Deviation 0.4816	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 5	1.268 Millimoles per liter Standard Deviation 0.6846	1.044 Millimoles per liter Standard Deviation 0.4087	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 7	1.200 Millimoles per liter Standard Deviation 0.5402	1.461 Millimoles per liter Standard Deviation 0.7119	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Baseline (Day -1)	4.477 Millimoles per liter Standard Deviation 0.8449	4.454 Millimoles per liter Standard Deviation 0.7606	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 2	4.603 Millimoles per liter Standard Deviation 0.7998	4.531 Millimoles per liter Standard Deviation 0.8227	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 5	4.591 Millimoles per liter Standard Deviation 0.8199	4.287 Millimoles per liter Standard Deviation 0.9845	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 7	4.173 Millimoles per liter Standard Deviation 0.7740	4.617 Millimoles per liter Standard Deviation 0.8221	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion Gap, Baseline (Day -1)	9.5 Millimoles per liter Standard Deviation 0.87	9.2 Millimoles per liter Standard Deviation 0.92	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion Gap, Day 2	9.9 Millimoles per liter Standard Deviation 0.85	10.4 Millimoles per liter Standard Deviation 0.98	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion Gap, Day 5	9.6 Millimoles per liter Standard Deviation 0.92	9.0 Millimoles per liter Standard Deviation 2.83	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion Gap, Day 7	9.3 Millimoles per liter Standard Deviation 0.87	9.6 Millimoles per liter Standard Deviation 0.88	—

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Baseline (Day -1)	74.58 Micromoles per liter Standard Deviation 13.770	77.79 Micromoles per liter Standard Deviation 14.328	75.32 Micromoles per liter Standard Deviation 15.250
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 2	82.89 Micromoles per liter Standard Deviation 15.880	84.90 Micromoles per liter Standard Deviation 17.025	81.47 Micromoles per liter Standard Deviation 15.445
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 5	76.77 Micromoles per liter Standard Deviation 9.046	77.20 Micromoles per liter Standard Deviation 17.447	79.57 Micromoles per liter Standard Deviation 18.646
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 7	82.05 Micromoles per liter Standard Deviation 14.136	78.55 Micromoles per liter Standard Deviation 15.613	74.53 Micromoles per liter Standard Deviation 13.793
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Baseline (Day -1)	1.93 Micromoles per liter Standard Deviation 0.540	2.03 Micromoles per liter Standard Deviation 0.597	2.03 Micromoles per liter Standard Deviation 0.634
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 2	1.80 Micromoles per liter Standard Deviation 0.532	1.97 Micromoles per liter Standard Deviation 0.678	2.03 Micromoles per liter Standard Deviation 0.687
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 5	1.67 Micromoles per liter Standard Deviation 0.437	2.08 Micromoles per liter Standard Deviation 0.694	2.28 Micromoles per liter Standard Deviation 0.778
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 7	2.00 Micromoles per liter Standard Deviation 0.548	1.88 Micromoles per liter Standard Deviation 0.577	2.04 Micromoles per liter Standard Deviation 0.648
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Baseline (Day -1)	10.38 Micromoles per liter Standard Deviation 3.283	11.43 Micromoles per liter Standard Deviation 3.510	10.93 Micromoles per liter Standard Deviation 3.805
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 2	9.70 Micromoles per liter Standard Deviation 2.714	11.04 Micromoles per liter Standard Deviation 3.619	10.72 Micromoles per liter Standard Deviation 3.862
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 5	8.38 Micromoles per liter Standard Deviation 3.021	9.95 Micromoles per liter Standard Deviation 3.605	11.05 Micromoles per liter Standard Deviation 3.553
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 7	10.92 Micromoles per liter Standard Deviation 2.975	10.34 Micromoles per liter Standard Deviation 3.510	10.11 Micromoles per liter Standard Deviation 3.473
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Baseline (Day -1)	287.0 Micromoles per liter Standard Deviation 67.20	291.8 Micromoles per liter Standard Deviation 58.22	276.0 Micromoles per liter Standard Deviation 58.76
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 2	280.1 Micromoles per liter Standard Deviation 64.07	283.9 Micromoles per liter Standard Deviation 62.39	271.9 Micromoles per liter Standard Deviation 54.52
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 5	235.0 Micromoles per liter Standard Deviation 40.83	290.5 Micromoles per liter Standard Deviation 53.91	292.3 Micromoles per liter Standard Deviation 53.16
Part 1: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 7	305.1 Micromoles per liter Standard Deviation 55.55	271.8 Micromoles per liter Standard Deviation 58.66	280.0 Micromoles per liter Standard Deviation 53.36

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Baseline (Day -1)	81.02 Micromoles per liter Standard Deviation 17.857	83.19 Micromoles per liter Standard Deviation 19.817	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 2	88.29 Micromoles per liter Standard Deviation 21.603	90.17 Micromoles per liter Standard Deviation 22.148	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 5	85.31 Micromoles per liter Standard Deviation 13.191	83.79 Micromoles per liter Standard Deviation 24.894	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Creatinine, Day 7	82.51 Micromoles per liter Standard Deviation 25.513	82.90 Micromoles per liter Standard Deviation 12.663	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Baseline (Day -1)	1.71 Micromoles per liter Standard Deviation 0.506	1.73 Micromoles per liter Standard Deviation 0.470	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 2	1.69 Micromoles per liter Standard Deviation 0.431	1.77 Micromoles per liter Standard Deviation 0.621	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 5	1.89 Micromoles per liter Standard Deviation 0.295	1.99 Micromoles per liter Standard Deviation 0.851	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Direct bilirubin, Day 7	1.62 Micromoles per liter Standard Deviation 0.565	1.72 Micromoles per liter Standard Deviation 0.286	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Baseline (Day -1)	9.64 Micromoles per liter Standard Deviation 3.401	9.27 Micromoles per liter Standard Deviation 2.548	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 2	8.98 Micromoles per liter Standard Deviation 1.548	9.58 Micromoles per liter Standard Deviation 3.048	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 5	9.55 Micromoles per liter Standard Deviation 1.125	10.50 Micromoles per liter Standard Deviation 5.312	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Bilirubin, Day 7	8.57 Micromoles per liter Standard Deviation 3.324	9.90 Micromoles per liter Standard Deviation 0.758	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Baseline (Day -1)	324.4 Micromoles per liter Standard Deviation 66.68	329.2 Micromoles per liter Standard Deviation 73.48	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 2	307.0 Micromoles per liter Standard Deviation 64.72	331.8 Micromoles per liter Standard Deviation 81.70	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 5	330.1 Micromoles per liter Standard Deviation 68.86	306.0 Micromoles per liter Standard Deviation 73.64	—
Part 2: Absolute Values of Clinical Chemistry Parameters: Creatinine, Direct Bilirubin, Bilirubin, and Urate Urate, Day 7	308.0 Micromoles per liter Standard Deviation 74.35	332.3 Micromoles per liter Standard Deviation 62.07	—

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 2	-0.1 International units per Liter Standard Deviation 2.49	-1.7 International units per Liter Standard Deviation 4.74	-0.5 International units per Liter Standard Deviation 5.50
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 5	-1.7 International units per Liter Standard Deviation 4.37	-0.2 International units per Liter Standard Deviation 2.23	-3.0 International units per Liter Standard Deviation 8.39
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 7	1.1 International units per Liter Standard Deviation 5.97	-0.3 International units per Liter Standard Deviation 9.32	0.5 International units per Liter Standard Deviation 7.93
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 2	1.8 International units per Liter Standard Deviation 5.14	2.0 International units per Liter Standard Deviation 3.76	1.8 International units per Liter Standard Deviation 4.66
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 5	-1.8 International units per Liter Standard Deviation 3.25	-1.0 International units per Liter Standard Deviation 5.66	-2.7 International units per Liter Standard Deviation 6.74
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 7	1.4 International units per Liter Standard Deviation 3.67	0.8 International units per Liter Standard Deviation 3.75	3.9 International units per Liter Standard Deviation 5.55
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 2	-0.5 International units per Liter Standard Deviation 1.65	-0.9 International units per Liter Standard Deviation 2.32	0.0 International units per Liter Standard Deviation 3.08
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 5	-2.0 International units per Liter Standard Deviation 2.90	0.3 International units per Liter Standard Deviation 1.63	0.0 International units per Liter Standard Deviation 3.58
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 7	-0.4 International units per Liter Standard Deviation 2.06	-0.9 International units per Liter Standard Deviation 3.62	0.6 International units per Liter Standard Deviation 2.76
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 2	-0.1 International units per Liter Standard Deviation 2.24	0.0 International units per Liter Standard Deviation 1.43	0.6 International units per Liter Standard Deviation 3.76
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 5	-3.0 International units per Liter Standard Deviation 4.20	-1.3 International units per Liter Standard Deviation 1.86	-1.0 International units per Liter Standard Deviation 2.28
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 7	-0.1 International units per Liter Standard Deviation 3.11	-1.2 International units per Liter Standard Deviation 2.48	2.4 International units per Liter Standard Deviation 8.13
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 2	-2.6 International units per Liter Standard Deviation 11.67	-0.9 International units per Liter Standard Deviation 10.41	4.0 International units per Liter Standard Deviation 9.89
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 5	-16.5 International units per Liter Standard Deviation 14.90	0.3 International units per Liter Standard Deviation 7.26	2.2 International units per Liter Standard Deviation 14.15
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 7	-8.8 International units per Liter Standard Deviation 10.09	-10.2 International units per Liter Standard Deviation 9.54	-5.3 International units per Liter Standard Deviation 15.43
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 2	-11.4 International units per Liter Standard Deviation 33.22	-10.3 International units per Liter Standard Deviation 20.22	0.2 International units per Liter Standard Deviation 27.16
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 5	-18.5 International units per Liter Standard Deviation 20.66	-1.8 International units per Liter Standard Deviation 11.58	8.8 International units per Liter Standard Deviation 13.75
Part 1: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 7	-26.2 International units per Liter Standard Deviation 43.88	-27.3 International units per Liter Standard Deviation 43.24	-9.3 International units per Liter Standard Deviation 22.62

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=16 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 2	-0.7 International units per Liter Standard Deviation 3.48	0.1 International units per Liter Standard Deviation 3.30	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 5	1.1 International units per Liter Standard Deviation 2.64	3.4 International units per Liter Standard Deviation 7.21	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALT, Day 7	1.6 International units per Liter Standard Deviation 5.77	2.2 International units per Liter Standard Deviation 3.67	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 2	-0.1 International units per Liter Standard Deviation 4.22	0.4 International units per Liter Standard Deviation 3.65	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 5	1.1 International units per Liter Standard Deviation 3.56	3.9 International units per Liter Standard Deviation 9.20	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK ALP, Day 7	1.0 International units per Liter Standard Deviation 3.81	2.1 International units per Liter Standard Deviation 4.26	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 2	-0.8 International units per Liter Standard Deviation 2.32	-0.7 International units per Liter Standard Deviation 1.81	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 5	1.4 International units per Liter Standard Deviation 1.06	2.4 International units per Liter Standard Deviation 3.32	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK AST, Day 7	0.7 International units per Liter Standard Deviation 2.55	0.1 International units per Liter Standard Deviation 1.69	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 2	-0.3 International units per Liter Standard Deviation 1.08	0.5 International units per Liter Standard Deviation 1.38	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 5	0.9 International units per Liter Standard Deviation 0.83	2.0 International units per Liter Standard Deviation 3.67	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK GGT, Day 7	-1.6 International units per Liter Standard Deviation 3.09	-0.9 International units per Liter Standard Deviation 2.71	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 2	-7.1 International units per Liter Standard Deviation 11.65	-4.9 International units per Liter Standard Deviation 8.68	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 5	-4.6 International units per Liter Standard Deviation 10.89	3.3 International units per Liter Standard Deviation 16.90	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK LDH, Day 7	-4.8 International units per Liter Standard Deviation 12.02	-2.7 International units per Liter Standard Deviation 11.92	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 2	-6.9 International units per Liter Standard Deviation 12.25	-13.4 International units per Liter Standard Deviation 20.32	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 5	7.6 International units per Liter Standard Deviation 11.56	2.1 International units per Liter Standard Deviation 13.70	—
Part 2: Change From Baseline in Chemistry Parameters: ALT, ALP, AST, GGT, LDH, CK CK, Day 7	-16.3 International units per Liter Standard Deviation 34.30	-23.1 International units per Liter Standard Deviation 36.97	—

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=22 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=21 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) n=20 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 2	0.014 Millimoles per liter Standard Deviation 0.0547	0.011 Millimoles per liter Standard Deviation 0.0599	0.033 Millimoles per liter Standard Deviation 0.0838
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 5	-0.007 Millimoles per liter Standard Deviation 0.0333	0.013 Millimoles per liter Standard Deviation 0.0432	0.007 Millimoles per liter Standard Deviation 0.0535
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 7	0.011 Millimoles per liter Standard Deviation 0.0650	-0.002 Millimoles per liter Standard Deviation 0.0867	0.018 Millimoles per liter Standard Deviation 0.0875
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 2	-1.1 Millimoles per liter Standard Deviation 1.41	-0.5 Millimoles per liter Standard Deviation 1.33	-0.5 Millimoles per liter Standard Deviation 1.57
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 5	-1.7 Millimoles per liter Standard Deviation 1.37	-0.8 Millimoles per liter Standard Deviation 1.17	-1.7 Millimoles per liter Standard Deviation 1.63
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 7	-0.5 Millimoles per liter Standard Deviation 1.69	0.4 Millimoles per liter Standard Deviation 2.22	0.0 Millimoles per liter Standard Deviation 1.05
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 2	0.3 Millimoles per liter Standard Deviation 1.94	-0.1 Millimoles per liter Standard Deviation 1.15	-0.1 Millimoles per liter Standard Deviation 1.47
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 5	1.7 Millimoles per liter Standard Deviation 2.25	-0.3 Millimoles per liter Standard Deviation 1.03	-1.5 Millimoles per liter Standard Deviation 2.51
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 7	0.2 Millimoles per liter Standard Deviation 1.89	0.8 Millimoles per liter Standard Deviation 2.17	-0.1 Millimoles per liter Standard Deviation 2.23
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 2	-0.197 Millimoles per liter Standard Deviation 0.2209	-0.135 Millimoles per liter Standard Deviation 0.2856	-0.262 Millimoles per liter Standard Deviation 0.1809
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 5	-0.093 Millimoles per liter Standard Deviation 0.2550	-0.035 Millimoles per liter Standard Deviation 0.1792	-0.105 Millimoles per liter Standard Deviation 0.1735
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 7	-0.086 Millimoles per liter Standard Deviation 0.3962	-0.066 Millimoles per liter Standard Deviation 0.3024	-0.171 Millimoles per liter Standard Deviation 0.1920
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 2	0.02 Millimoles per liter Standard Deviation 0.234	-0.18 Millimoles per liter Standard Deviation 0.274	0.03 Millimoles per liter Standard Deviation 0.281
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 5	0.10 Millimoles per liter Standard Deviation 0.290	-0.05 Millimoles per liter Standard Deviation 0.226	-0.20 Millimoles per liter Standard Deviation 0.369
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 7	0.10 Millimoles per liter Standard Deviation 0.310	-0.06 Millimoles per liter Standard Deviation 0.198	-0.08 Millimoles per liter Standard Deviation 0.361
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 2	0.0 Millimoles per liter Standard Deviation 1.95	1.64 Millimoles per liter Standard Deviation 0.3	0.3 Millimoles per liter Standard Deviation 2.24
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 5	1.0 Millimoles per liter Standard Deviation 1.79	-0.2 Millimoles per liter Standard Deviation 1.17	-1.3 Millimoles per liter Standard Deviation 2.66
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 7	-0.2 Millimoles per liter Standard Deviation 2.36	0.4 Millimoles per liter Standard Deviation 2.14	-0.3 Millimoles per liter Standard Deviation 2.31
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 2	0.520 Millimoles per liter Standard Deviation 0.7073	0.333 Millimoles per liter Standard Deviation 0.4752	0.4553 Millimoles per liter Standard Deviation 0.4553
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 5	0.857 Millimoles per liter Standard Deviation 0.4584	0.143 Millimoles per liter Standard Deviation 0.5844	-0.017 Millimoles per liter Standard Deviation 0.6301
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 7	0.618 Millimoles per liter Standard Deviation 0.7434	-0.035 Millimoles per liter Standard Deviation 0.5511	0.309 Millimoles per liter Standard Deviation 0.7935
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 2	0.069 Millimoles per liter Standard Deviation 0.1242	0.078 Millimoles per liter Standard Deviation 0.0972	0.082 Millimoles per liter Standard Deviation 0.0716
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 5	0.082 Millimoles per liter Standard Deviation 0.1232	0.048 Millimoles per liter Standard Deviation 0.0952	-0.002 Millimoles per liter Standard Deviation 0.0964
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 7	0.036 Millimoles per liter Standard Deviation 0.1218	0.099 Millimoles per liter Standard Deviation 0.1245	0.052 Millimoles per liter Standard Deviation 0.0487
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 2	0.095 Millimoles per liter Standard Deviation 0.3467	-0.013 Millimoles per liter Standard Deviation 0.2499	0.011 Millimoles per liter Standard Deviation 0.2280
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 5	-0.192 Millimoles per liter Standard Deviation 0.1338	-0.223 Millimoles per liter Standard Deviation 0.3551	-0.185 Millimoles per liter Standard Deviation 0.1778
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 7	0.160 Millimoles per liter Standard Deviation 0.4290	-0.149 Millimoles per liter Standard Deviation 0.2656	-0.016 Millimoles per liter Standard Deviation 0.1888
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 2	0.117 Millimoles per liter Standard Deviation 0.3551	0.058 Millimoles per liter Standard Deviation 0.3115	0.052 Millimoles per liter Standard Deviation 0.2865
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 5	-0.098 Millimoles per liter Standard Deviation 0.5254	-0.022 Millimoles per liter Standard Deviation 0.4323	-0.252 Millimoles per liter Standard Deviation 0.3485
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 7	-0.033 Millimoles per liter Standard Deviation 0.4137	-0.137 Millimoles per liter Standard Deviation 0.4751	0.056 Millimoles per liter Standard Deviation 0.3841
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 2	0.8 Millimoles per liter Standard Deviation 2.07	0.3 Millimoles per liter Standard Deviation 1.59	0.8 Millimoles per liter Standard Deviation 2.36
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 5	1.0 Millimoles per liter Standard Deviation 1.41	1.2 Millimoles per liter Standard Deviation 1.17	1.7 Millimoles per liter Standard Deviation 1.37
Part 1: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 7	0.4 Millimoles per liter Standard Deviation 1.29	-0.8 Millimoles per liter Standard Deviation 1.88	-0.4 Millimoles per liter Standard Deviation 1.35

Measure	Part 1:Treatment A:GSK3640254 25mg+GSK3640254 100mg+DTG 50 mg n=17 Participants Participants received a single oral dose of GSK3640254 25 mg (2 tablets), GSK3640254 100 mg (1 tablet), and DTG 50 mg (1 tablet) together under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment B:GSK3640254/DTG 150/50 mg(Monolayer Tablet) n=18 Participants Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 monolayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.	Part 1:Treatment C:GSK3640254/DTG 150/50mg(Bilayer Tablet) Participants received a single oral dose of GSK3640254 / DTG, 150 mg/50 mg (1 bilayer tablet) FDC under moderate fat and calorie conditions on Day 1 in treatment period 1, 2 and 3.
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 2	-0.008 Millimoles per liter Standard Deviation 0.0764	0.007 Millimoles per liter Standard Deviation 0.0585	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 5	-0.033 Millimoles per liter Standard Deviation 0.0812	0.019 Millimoles per liter Standard Deviation 0.0971	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Calcium, Day 7	-0.002 Millimoles per liter Standard Deviation 0.0814	-0.007 Millimoles per liter Standard Deviation 0.0779	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 2	0.01 Millimoles per liter Standard Deviation 0.247	0.09 Millimoles per liter Standard Deviation 0.289	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 2	-1.3 Millimoles per liter Standard Deviation 1.49	-1.0 Millimoles per liter Standard Deviation 1.37	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 5	-1.1 Millimoles per liter Standard Deviation 0.99	-0.6 Millimoles per liter Standard Deviation 0.73	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap CO2, Day 7	0.2 Millimoles per liter Standard Deviation 1.48	0.3 Millimoles per liter Standard Deviation 1.41	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 2	0.3 Millimoles per liter Standard Deviation 1.85	-0.4 Millimoles per liter Standard Deviation 1.89	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 5	0.4 Millimoles per liter Standard Deviation 2.00	-0.9 Millimoles per liter Standard Deviation 1.90	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Chloride, Day 7	0.4 Millimoles per liter Standard Deviation 1.88	0.2 Millimoles per liter Standard Deviation 2.33	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 2	-0.084 Millimoles per liter Standard Deviation 0.1480	0.077 Millimoles per liter Standard Deviation 0.2392	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 5	-0.160 Millimoles per liter Standard Deviation 0.2754	-0.256 Millimoles per liter Standard Deviation 0.3867	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Glucose, Day 7	0.019 Millimoles per liter Standard Deviation 0.3691	-0.087 Millimoles per liter Standard Deviation 0.2601	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 5	-0.01 Millimoles per liter Standard Deviation 0.476	-0.08 Millimoles per liter Standard Deviation 0.192	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Potassium, Day 7	0.01 Millimoles per liter Standard Deviation 0.145	0.18 Millimoles per liter Standard Deviation 0.393	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 2	-0.4 Millimoles per liter Standard Deviation 1.41	-0.3 Millimoles per liter Standard Deviation 2.24	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 5	-0.8 Millimoles per liter Standard Deviation 1.49	-0.8 Millimoles per liter Standard Deviation 1.86	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Sodium, Day 7	0.6 Millimoles per liter Standard Deviation 1.33	1.2 Millimoles per liter Standard Deviation 2.22	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 2	0.228 Millimoles per liter Standard Deviation 0.4467	0.628 Millimoles per liter Standard Deviation 0.7585	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 5	-0.138 Millimoles per liter Standard Deviation 0.6950	0.067 Millimoles per liter Standard Deviation 0.8951	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Urea nitrogen, Day 7	0.321 Millimoles per liter Standard Deviation 0.7415	0.441 Millimoles per liter Standard Deviation 0.7504	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 2	0.041 Millimoles per liter Standard Deviation 0.0842	0.044 Millimoles per liter Standard Deviation 0.0902	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 5	0.014 Millimoles per liter Standard Deviation 0.0983	0.012 Millimoles per liter Standard Deviation 0.0349	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Phosphate, Day 7	0.023 Millimoles per liter Standard Deviation 0.0854	0.019 Millimoles per liter Standard Deviation 0.0862	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 2	-0.111 Millimoles per liter Standard Deviation 0.3084	-0.121 Millimoles per liter Standard Deviation 0.2674	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 5	-0.215 Millimoles per liter Standard Deviation 0.3208	-0.156 Millimoles per liter Standard Deviation 0.2584	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Triglycerides, Day 7	-0.089 Millimoles per liter Standard Deviation 0.4124	-0.031 Millimoles per liter Standard Deviation 0.2996	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 2	0.121 Millimoles per liter Standard Deviation 0.4047	0.076 Millimoles per liter Standard Deviation 0.2377	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 5	-0.036 Millimoles per liter Standard Deviation 0.3000	0.113 Millimoles per liter Standard Deviation 0.4685	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Cholesterol, Day 7	-0.170 Millimoles per liter Standard Deviation 0.4438	-0.119 Millimoles per liter Standard Deviation 0.4662	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 2	0.5 Millimoles per liter Standard Deviation 0.82	1.3 Millimoles per liter Standard Deviation 0.96	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 5	0.0 Millimoles per liter Standard Deviation 1.41	-0.3 Millimoles per liter Standard Deviation 3.08	—
Part 2: Change From Baseline in Clinical Chemistry Parameters: Calcium, CO2, Chloride, Glucose, Potassium, Sodium, Urea Nitrogen, Phosphorus, Triglycerides, Cholesterol, and Anion Gap Anion gap, Day 7	-0.1 Millimoles per liter Standard Deviation 0.78	0.6 Millimoles per liter Standard Deviation 1.42	—